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Introducción General 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
a) Presentación de los trabajos 
 
Los trabajos compendiados que constituyen el cuerpo de la presente tesis están 
relacionados con la infección por el Parvovirus humano B19 (B19V), los cuadros 
dermatopatológicos ocasionados por la misma y la hipótesis de que la detección aislada 
en biopsias cutáneas de ácido desoxirribonucleico (ADN) de B19V no constituye 
necesariamente prueba de relación causal entre aquella y estos, pues el virus es capaz de 
permanecer en los tejidos mucho tiempo después de ocurrida la infección. Tal relación 
debe basarse en determinaciones analíticas (seroconversión, presencia de ADN vírico en 
sangre) o confirmación de la presencia de material del virión en los tejidos, como la 
demostración de proteína vírica (Viral Protein 2, VP2) en el endotelio de vasos dérmicos. 
Esta última apoya la tesis de que el virus penetra en células generalmente poco permisivas 
valiéndose de un mecanismo de estímulo mediado por anticuerpos, en el curso de la 
primera fase de la infección. 
 
En el primero de los trabajos (Immunohistochemistry in the Diagnosis of 
Cutaneous Viral Infections) se detalla la aportación de la inmunohistoquímica al 
diagnóstico de infección reciente por B19V, en el marco de un estudio global de 
infecciones víricas de la piel. En el segundo (Detection of human parvovirus B19 DNA 
in 22% of 1,815 cutaneous biopsies of a wide variety of dermatologic conditions 
suggests viral persistence after primary infection and casts doubts on its pathogenic 
significance) se estudian los patrones histopatológicos de una amplia serie de muestras 
de biopsia con positividad para ADN de B19V, planteándose la falta de correlación entre 
esta circunstancia y la patogenicidad del virus; y en el tercero (Immunohistochemical 
demonstration of Parvovirus B19 VP2 protein in periflexular exantema in an adult, 
supporting antibody-dependent enhancement as means of endotelial uptake of the 
virus) se amplia la detección inmunohistoquímica en biopsia de proteína de B19V a un 
ejemplo de erupción flexural como manifestación de primoinfección. 
 
 
b) Justificación de la temática 
 
 El B19V, el mejor conocido de los parvovirus capaces de infectar al ser humano 
(1-3), es el agente causal de la enfermedad exantemática infantil denominada “quinta 
enfermedad” (eritema infeccioso, EI) (8). Está involucrado asimismo en cuadros 
reumatológicos (artropatía aguda o crónica (9) ), aplasia medular transitoria y anemia en 
pacientes inmunodeprimidos, y contribuye a la patogénesis de una de las formas de 
hidrops fetal de origen no inmunológico (9). Además, se ha detectado ADN o VP2 de 
B19V por diferentes métodos en numerosos tejidos (médula ósea, cerebro, intestinos 
delgado y grueso, corazón, riñón, hígado, pulmón, tejido linfoide, estómago, sinovial, 
testículo y tiroides). Por este motivo, se ha implicado a B19V en la patogénesis de una 
amplia gama de enfermedades, que comprenden la miocardiopatía dilatada, la 
enfermedad de Kikuchi-Fujimoto, linfomas, gangrena no oclusiva de estómago e 
intestino, carcinoma de intestino grueso, tumores testiculares y enfermedades 
tiroideas(10). 
 
 
  Se han descrito tres genotipos de B19V, que se diferencian en un 10% de su 
genoma (3,11): el genotipo 1 (el más extendido), el genotipo 2 (restringido a sujetos 
nacidos antes de 1973), y el genotipo 3 (detectado en África occidental y escasos países 
occidentales) (12). El virus se identificó en 1975 en el suero de nueve donantes de sangre 
sanos, un paciente con hepatitis aguda y otro portador de un trasplante renal reciente, en 
forma de resultados falsamente positivos en el cribado rutinario de suero para detectar 
antígeno de superficie de la hepatitis B (13). Desde que en 1983 se confirmara su relación 
con la quinta enfermedad (8) (a su vez conocida desde el siglo XVIII(14)), se ha descrito 
su asociación con diversos procesos dermatológicos, implicándolo en la patogénesis de 
numerosos cuadros clínicos. Estos abarcan desde entidades infrecuentes con una fuerte 
asociación etiológica con B19V, como la erupción papular y purpúrica “en guantes y 
calcetines” (EPPGC) (15), hasta afecciones dermatológicas clásicas sin aparente relación 
con el virus. La lista de entidades incluye la púrpura de Henoch-Schönlein, el eritema 
multiforme, erupciones semejantes a dermatomiositis, urticaria crónica, esclerosis 
sistémica, pitiriasis liquenoide, psoriasis, enfermedad de Behçet, granuloma anular, 
síndrome de Wells, lupus eritematoso y esclerodermia (4-6,16-43) 
 
 La asociación causal entre B19V y las diferentes enfermedades (cutáneas y 
sistémicas) con las que se lo ha relacionado se ha basado en determinaciones analíticas 
de diferentes tipos: serología para detección de anticuerpos (IgM seguido de 
seroconversión), detección de ADN de B19V en suero o tejido, y detección de proteínas 
víricas (VP2) en tejido mediante inmunohistoquímica (10). Sin embargo, la detección del 
ADN de B19V mediante reacción en cadena de la polimerasa (PCR) en piel sana y en 
lesiones cutáneas muy dispares sugiere que B19V persiste en los tejidos mucho tiempo 
después de la infección inicial (para esta persistencia se ha creado el término “Portafolios 
biológico” (44)) , lo que restaría valor a la mera detección del ADN. Los trabajos previos 
a los aquí presentados han estudiado casos aislados o series cortas de pacientes. Así, se 
encontró ADN de B19V en biopsias cutáneas de 9 pacientes con pitiriasis liquenoide (32); 
en 18 de 36 pacientes con urticaria crónica y 14 de 22 sujetos sanos (30); y en  30 de 121 
con piel normal, nevus, melanomas o pitiriasis liquenoide.(45)  
 
Por otro lado, la demostración en biopsias de piel mediante inmunofluorescencia 
o inmunohistoquímica de la proteína vírica VP2 se ha comunicado en muy escasas 
ocasiones en pacientes con cuadros clínicos asociados (por estudio serológico) a infección 
por B19V. Así, Schwarz et al (17) detectaron mediante inmunofluorescencia indirecta 
positividad en los queratinocitos epidérmicos en la muestra cutánea de un eritema 
infeccioso en un niño. Takahashi et al (46) observaron mediante inmunohistoquímica 
material positivo granular en el citoplasma de las células endoteliales de la dermis en una 
paciente de 37 años con una erupción generalizada, y partículas víricas en la misma 
localización mediante microscopia electrónica. Tanto los queratinocitos como el epitelio 
de glándulas ecrinas y el endotelio de vasos dérmicos mostraron positividad 
inmunohistoquímica para la proteína VP2 en tres pacientes con EPPGC en el trabajo de 
Aractingi et al (5). En aportación más reciente se observó por nuestro grupo positividad 
mediante inmunohistoquímica en el citoplasma de células endoteliales dérmicas en tres 
casos de EPPGC (7). 
 
 
 
 
c) Aportación original 
 
He estudiado mediante PCR la presencia de ADN de B19V en un gran número de biopsias 
dermatológicas, caracterizado los diferentes cuadros histopatológicos y entidades clínicas 
correspondientes, y contribuido con ello a una mayor precisión en la asignación del virus 
a la patogenia de las numerosas enfermedades cutáneas con las que se lo ha relacionado 
en la literatura previa. Además, he aportado datos inmunohistoquímicos que certifican la 
presencia de B19V en biopsias cutáneas, en diferentes exantemas en el curso de 
primoinfección (erupción purpúrica y papular “en guantes y calcetines” y exantema 
flexural). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Resumen de los resultados obtenidos 
 
 
 
 
 
 
 
 
 
 
 
 
En el estudio molecular realizado (PCR) se detectó ADN de B19V en 402 de 1.825 
biopsias cutáneas (22%), correspondientes a 1.749 pacientes.  
Los cuadros dermatológicos que motivaron la toma de biopsia en los 402 casos positivos 
se clasificaron en once grupos: 
 
1) Patología inflamatoria de la unidad folículo-sebácea-apocrina 
2) Dermatosis papulosas, eritematosas, descamativas y urticariformes 
3) Enfermedades ampollosas 
4) Dermatosis anulares-policlíclicas 
5) Enfermedades granulomatosas, histiocitosis, mastocitosis 
6) Enfermedades infecciosas 
7) Lesiones nodulares 
8) Vasculitis y procesos de reactividad vascular 
9) Depósitos 
10) Colagenosis 
11) Malformaciones, hamartomas, hiperplasias y neoplasias benignas 
 
En estos once grupos se recogen un total de 586 entidades clínicas o 
clinicopatológicas, pues en muchas ocasiones se aportaba más de una opción diagnóstica 
por el dermatólogo que remitía el caso. 
 
Las entidades más frecuentes fueron vasculitis (40 casos), pitiriasis liquenoide 
(38), pitiriasis rosada (33), dermatitis-eczema (27), liquen plano-liquen nitidus (19), 
psoriasis (18), púrpura (18), eritema crónico migratorio-borreliosis (17) y granuloma 
anular (16). 
 Los patrones histopatólógicos de dichas muestras abarcaron todo el espectro de 
afectación histológica (perivascular y variantes, nodular, difuso, vasculitis…) 
reconocidos en la literatura (47) 
 
Por otro lado, la detección inmunohistoquímica de VP2 fue únicamente observada 
en tres casos de SPPGC y en una erupción mixta flexural y purpúrica (esta última, objeto 
de una publicación independiente). 
 
Estos resultados apoyan la persistencia de B19V en el organismo humano tras la 
primoinfección (en la infancia o en la edad adulta), aunque se desconoce el mecanismo 
exacto de latencia-persistencia vírica. Solamente si se detecta ADN tisular en el contexto 
de una infección aguda demostrable serológicamente (conversión de anticuerpos, 
detección de ADN de B19V en suero), puede atribuirse el cuadro clínico al virus. La 
detección de VP2 en el interior de células implica participación patogénica del virus, 
quizá con captación estimulada por mecanismo mediado por anticuerpos. 
 
En conclusión, los datos aportados (positividad para ADN vírico mediante PCR 
en el 22% de las muestras) indican que es posible detectar ADN de B19V en gran número 
de procesos dermatológicos, que abarcan numerosas entidades clínicas y todo el espectro 
de patrones lesionales histopatológicos. Por lo tanto, el simple hallazgo de B19V en 
muestras de tejido no basta para probar una relación causal con la enfermedad en cuestión. 
Estos datos presumiblemente puedan validarse en muestras de otros órganos (corazón, 
tiroides…), en los que se ha asumido igualmente una participación patogénica de B19V 
sobre la base de resultados moleculares. 
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CME ARTICLE
Immunohistochemistry in the Diagnosis of Cutaneous Viral
Infections—Part I. Cutaneous Viral Infections by
Herpesviruses and Papillomaviruses
Ana M. Molina-Ruiz, MD,* Carlos Santonja, MD,† Arno Rütten, MD,‡ Lorenzo Cerroni, MD,§
Heinz Kutzner, MD,‡ and Luis Requena, MD*
Background: Cutaneous viral infections are of increasing clinical
importance, particularly in patients who are immunocompromised.
Objective: The use of immunohistochemistry (IHC) in the
diagnosis of cutaneous infections provides a rapid morphological
diagnosis and can be applied to conﬁrm the diagnosis of speciﬁc
viral infections that may be difﬁcult to diagnose with certainty
using routine microscopy alone, thus facilitating clinical decisions
in patient care.
Methods: Several immunostains for speciﬁc viruses that have been
useful in dermatopathology are reviewed. Emphasis is placed on new
stains and novel uses of existing stains.
Results: This article is an up-to-date overview of the potential uses
and limitations of IHC in the histopathologic diagnosis of cutaneous
viral infections by herpesviruses and papillomaviruses.
Limitations: Whereas speciﬁc monoclonal antibodies effectively
distinguish infections by herpes simplex virus-1, herpes simplex
virus-2, varicella zoster virus, Epstein–Barr virus, and cytomegalo-
virus, IHC does not distinguish between the 120 antigenically dis-
tinct strains of human papillomavirus.
Conclusions: IHC may assist dermatopathologists to appropriately
diagnose viral infections caused by herpesviruses and papillomaviruses.
Key Words: immunohistochemistry, virus, skin, infection, herpes-
viruses, papillomaviruses
(Am J Dermatopathol 2015;37:1–14)
LEARNING OBJECTIVES
Upon completion of this learning activity, participants
should be better able to:
1. Use immunohistochemistry (IHC) to identify viral patho-
gens that are relevant to dermatopathology.
2. Apply these techniques in the diagnosis of cutaneous viral
infections and other related diseases.
INTRODUCTION
Various laboratory techniques can be used to assist in
the speciﬁc diagnosis of a suspected viral disease. These
include light and electron microscopy of a biopsy or smear,
serology, viral culture, and immunomorphological methods.
Although viral isolation in tissue culture remains the para-
mount diagnostic method, the development of monoclonal
antibodies to various viruses, for use with ﬂuorescent,
immunoperoxidase, and enzyme-linked immunosorbent assay
techniques, has made possible the rapid diagnosis of many
viral infections with a high degree of speciﬁcity.1 These
markers cannot replace the routine histologic study; however,
they can help to narrow the differential diagnosis.
Immunohistochemistry (IHC) continues to be one of the
main adjunctive methods to conventionally stained sections in
histopathology. This is mainly related to the fact that it is
a relatively simple, fast, and inexpensive method.2 Because of
technical advances, there has been a signiﬁcant increase in the
number of diagnostic immunohistochemical stains available for
pathologists and dermatopathologists in recent years. The sen-
sitivity and speciﬁcity of certain antibodies, their pattern of
staining (nuclear, cytoplasmic, or membranous), and back-
ground artifact must be considered in their interpretation. In
addition, evaluation must be done in relation to internal con-
trol.3 IHC, however, is only a tool to be used appropriately in
the context of clinical and histopathologic correlation; unrea-
sonable use can be misleading and ﬁnancially cost ineffective.4
In this review, we highlight the main immunohisto-
chemical available techniques that have been used and
continue to evolve in the diagnosis of mucocutaneous viral
infections and discuss their applicability.
IMMUNOHISTOCHEMISTRY
IHC has become an increasingly important histopatho-
logic tool over the past 20 years, and is now a key part of
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routine practice of dermatopathologists. IHC begins with
antigen retrieval by pretreating the tissue to unmask antigens
hidden by ﬁxatives, such as formalin. This step is often done
by microwaving the tissue in citrate buffer or other agents,
such as pepsin, proteases, or trypsin. Primary antibody is then
applied, which binds the antigens of interest. After washing
off the excess primary antibody, a secondary antibody is
added to bind the primary antibody. This is then followed by
the addition of an enzyme complex, such as avidin–biotin–
peroxidase complex, and a chromogen.2
Immunoperoxidase techniques involve the use of enzyme
labels that convert a colorless substrate into a colored one. The
most widely used enzymes are peroxidase and alkaline
phosphatase, and the most widely used substrates are diamino-
benzidine, amino ethylcarbazole, and nitroblue tetrazolium,
which, respectively, produce brown, red, and blue colors. These
markers can be attached, or conjugated, directly to the primary
antibody or indirectly using secondary antibodies or substances,
such as biotin and protein A.5
The use of a continuously increasing number of newly
raised and commercially available antibodies for IHC has
tremendously broadened IHC applicability, this being espe-
cially relevant for the diagnosis of different types of
infections.2,4,6 The use of IHC in the diagnosis of cutaneous
infections has recently been applied to conﬁrm the diagnosis
of speciﬁc viral infections that may be difﬁcult to diagnose
with certainty using routine microscopy alone.2,4,7,8 Table 1
lists the main commercially available antibodies for speciﬁc
viruses that can be useful in dermatopathology.
VIRAL PATHOGENS
Viruses are separated into families on the basis of the
type and form of the nucleic acid genome, of the morpholog-
ical features of the virus particle, and of the mode of
replication. There are 4 important families involved in
cutaneous viral diseases: the DNA families of Herpesviridae,
Papillomaviridae, and Poxviridae, and the RNA family
Picornaviridae.1 In addition to these 4 families, exanthemas
can occur in the course of infections with the following fam-
ilies: Adenoviridae, Reoviridae, Togaviridae, Flaviviridae, Ret-
roviridae, Parvoviridae, Paramyxoviridae, Arenaviridae,
Filoviridae, and Bunyaviridae.2,4,7,8 The 3 major DNA families
produce lesions that are histologically diagnostic for a disease
or group of diseases, whereas the other viruses, particularly the
RNA viruses, produce lesions that are often histopathologically
nonspeciﬁc, usually showing epidermal spongiosis and super-
ﬁcial perivascular lymphohistiocytic inﬁltrate.
MATERIALS AND METHODS
The biopsy specimens were ﬁxed in 10% buffered
formalin and embedded in parafﬁn. For routine histology,
5-mm-thick sections were stained with hematoxylin and eosin.
Immunohistochemical staining was performed both at the
Pathology Department of Fundación Jiménez Díaz University
Hospital in Madrid and the Dermatopathology Laboratory at
Friedrichshafen, Germany. Tissue sections were processed on
a BioTek Solutions TechMate 500 (Dako) where 1-hour
incubation with a primary antibody was performed. The immu-
nohistochemical study of the viral pathogens was performed
using the commercially available antibodies described in Table
1. Several antibodies for speciﬁc viruses described in the liter-
ature were not commercially available at the time of elabora-
tion of the article; therefore, immunohistochemical staining for
these pathogens could not be tested.
HERPESVIRUSES
More than 80 herpesviruses have been identiﬁed, 8 of
which are known human pathogens. Herpes simplex viruses
TABLE 1. Available Antibodies for Specific Viruses Useful in
Dermatopathology
Antibody Against Type/Clone
HSV-1 Rabbit polyclonal
DAKO
HSV-2 Rabbit polyclonal
DAKO
VZV Monoclonal, mouse
C90.2.8
Menarini
EBV Monoclonal, mouse
CS1-4
DAKO
CMV Monoclonal, mouse
CCH2 + DDG9
DAKO
HHV-6 Monoclonal/OHV-1, OHV-2, p41
HHV-7 Monoclonal/HHV-7 pp85
HHV-8 Monoclonal, mouse
13B10
Menarini
Papillomaviruses (HPV) HPV L1: monoclonal, mouse
Cytoimmune diagnostics
HPV cocktail: monoclonal, mouse
BPV-1/1H8 + CA
Zytomed systems
Parvovirus B19 (PVB19) Monoclonal, mouse
R92F6
Menarini
Merkel cell polyomavirus (MCPyV) Monoclonal, mouse
CM2B4
Santa Cruz Biotechnology
SV40 [trichodysplasia spinulosa
polyomavirus (TSPyV)]
Monoclonal, mouse
Pab101
BD Biosciences
HTLV-1 Monoclonal, mouse
1A3
Biozol
Measles Polyclonal, rabbit
Acris
Enterovirus Monoclonal, mouse
DAKO
ORF Parapoxvirus (ORF) Monoclonal
Ebola virus (EBO) EBO antigen
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(HSVs) belong to the ubiquitous Herpesviridae family of
viruses, which comprises HSV-1, HSV-2, varicella zoster
virus (VZV), cytomegalovirus (CMV), Epstein–Barr virus
(EBV), human herpesviruses (HHV) 6 and 7, and Kaposi
sarcoma (KS)–associated HHV-8.
Herpes Simplex Virus and Varicella Zoster
Virus
Histopathologic ﬁndings of biopsies of fully developed
labial and genital vesicles because of HSV and vesicles
caused by VZV consist of an intraepidermal blister with
varying degrees of epithelial necrosis.9 Two mechanisms are
involved in the formation of intraepidermal vesicles: one is
the ballooning of keratinocytes and the other is the reticular
degeneration of the epidermis.9 The most typical changes of
the infection are evident in the nuclei of epidermal keratino-
cytes, where there is peripheral margination of chromatin
attached to the nuclear membrane. As a consequence, the
keratinocytes show ringed nuclei with a homogeneous
ground-glass appearance combined with ballooning of the
nucleus. The earliest noteworthy abnormality in the cyto-
plasm of these keratinocytes is the presence of vacuolization.9
The histopathologic differential diagnosis of HSV and
VZV infections may be established immunohistochemically.
Immunoperoxidase stains speciﬁc for HSV-1 (Fig. 1), HSV-2
(Fig. 2), and VZV (Fig. 3) are available commercially.10,11 In
all cases, the cells exhibit both nuclear and cytoplasmic stain-
ing, although staining is more intense at the edges of the
infected nuclei, conﬁrming the histopathologic observation
of cells with peripheral margination of chromatin. The inten-
sity of staining varies between cells depending on the type of
infection. In infections by HSV-1 and HSV-2, epidermal
keratinocytes show the strongest staining and only occasion-
ally staining of the superﬁcial portion of the follicular infun-
dibulum can be observed. In early infections because of VZV,
however, the strongest staining is seen in the cells of the outer
root sheath of the hair follicle and in sebocytes of the seba-
ceous gland.12,13 IHC can also demonstrate VZV antigens in
nerves and other dermal structures. Epidermal keratinocytes,
on the contrary, tend to be negative for VZV, at least in the
early stages of infection.13 Based on such immunohistochem-
ical studies and the demonstration of viral antigens in various
cutaneous structures, it has been possible to establish the
sequence of herpes zoster lesion reactivation.9 A histopatho-
logic ﬁnding of folliculosebaceous involvement is character-
istic of incipient erythematous lesions, whereas epidermal
involvement and the formation of vesicles will be found in
fully developed lesions.9,13
Clinicians and pathologists may also wish to use
laboratory tests to establish deﬁnitive diagnosis in the case
of atypical cutaneous manifestations of these viruses. For
example, IHC was able to identify HSV infection in 5
bedridden geriatric patients (type 1 in 3 and type 2 in 2)
with genital ulcers when histology was suggestive of HSV
infection in only 2 of the 5 patients.14,15 Another study
showed that the sensitivity and speciﬁcity of IHC were com-
parable with in situ hybridization (ISH) in diagnosing HSV
infections.16 Similarly, IHC has also been shown to have
higher speciﬁcity and sensitivity than standard microscopic
assessments in diagnosing VZV infection through detection
of VZV ORF63 encoded protein (IE63) and VZV late protein
gE on both smears and formalin-ﬁxed parafﬁn-embedded skin
sections.10 This can be of special signiﬁcance in allowing
early diagnosis of VZV infection in immunocompromised
patients and thus early treatment. VZV infections may also
FIGURE 1. Histopathologic and
immunohistochemical findings in
a cutaneous infection by HSV-1 in the
upper lip. A, Scanning power showing
2 foci of epidermal involvement and
inflammatory infiltrate in the superfi-
cial dermis. B, Higher magnification
demonstrated the characteristic cyto-
pathic effect of herpesvirus infections
in epidermal keratinocytes. C, The
same case immunohistochemically
studied for HSV-1 antibody. D, Posi-
tivity in the nuclei and cytoplasm of
many epidermal keratinocytes. (A and
B, hematoxylin–eosin stain; C and D,
IHC for HSV-1. Original magnifica-
tions: A, ·10; B, ·400; C, ·10;
D, ·400.)
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be differentiated with certainty from HSV infections using
monoclonal antibodies against the VZV envelope glycopro-
tein gp1.17
Epstein–Barr Virus
EBV, or HHV-4, is a DNA g-herpes virus. The DNA
core is surrounded by an icosahedral nucleocapsid of 162
capsomers and the envelope. The EBV genome encodes for
nearly 100 viral proteins. This genome exists in 2 forms:
circular (episomal) and lineal. The episomal form is the one
adopted in latency periods, whereas the lineal form is the one
evidenced during the lytic phase in which EBV replicates.
EBV causes infectious mononucleosis, hairy leukoplakia
in patients with AIDS, Lipschütz ulcer (ulcus vulvae acutum),
FIGURE 2. Histopathologic and
immunohistochemical findings in
a persistent cutaneous infection by
HSV-2 in genital skin of a patient with
AIDS. A, Scanning power showing
irregular epidermal hyperplasia. B,
Higher magnification demonstrated
the characteristic cytopathic effect of
herpesvirus infections in epidermal
keratinocytes. C, The same case im-
munohistochemically studied for
HSV-2 antibody. D, Positivity in the
nuclei and cytoplasm of many epi-
dermal keratinocytes. (A and B,
hematoxylin–eosin stain; C and D,
IHC for HSV-2. Original magnifica-
tions: A, ·10; B, ·400; C, ·10;
D, ·400.)
FIGURE 3. Figure 1. Histopathologic
and immunohistochemical findings in
a necrotic herpes zoster infection
involving the lower back in a patient
with AIDS. A, Scanning power show-
ing epidermal necrosis and inflamma-
tory infiltrate involving the upper and
lower dermis. B, Higher magnification
demonstrated necrotic eccrine coils. C,
The same case immunohistochemi-
cally studied for VZV antibody show-
ing several foci of positivity in the
dermis. D, Positivity in the nuclei and
cytoplasm of many necrotic keratino-
cytes of the eccrine coils. (A and B,
hematoxylin–eosin stain; C and D, IHC
for VZV. Original magnifications:
A, ·10; B, ·400; C, ·10; D, ·400.)
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a variety of benign and malignant lymphoproliferative processes,
and nasopharyngeal lymphoepithelial carcinoma.9,17,18 In immu-
nosuppressed patients, mainly HIV-positive and transplanted
ones, an association between myoid tumors and EBV has
been well established. The spectrum of EBV-associated my-
oid tumors includes leiomyoma, smooth muscle tumor of
uncertain malignant potential, leiomyosarcoma, and myo-
pericytoma. In general, EBV-related myoid tumors show
some clinical peculiarities, such as being multifocal and
appearing in uncommon locations.19–28 EBV-associated leio-
myosarcoma shows a more indolent biological behavior than
classical leiomyosarcomas.24
In dermatology, it is also common to see a maculopap-
ular rash in patients with infectious mononucleosis who have
been treated with ampicillin, because of the presence of
immunoglobulin (Ig) G or IgM antibodies against penicillin,
but not IgE antibodies, as is the case in the hypersensitivity
reaction to penicillin. As mentioned above, histopathologic
ﬁndings in these rashes are nonspeciﬁc.
EBV displays a very high seroprevalence and is charac-
terized by its latent persistence in memory B lymphocytes. The
mere detection of EBV DNA therefore lacks diagnostic
relevance. Switching from latent to replicative infection has
only exceptionally been reported in B lymphocytes, and such
a lytic phenomenon mainly occurs in the epithelia.
There are commercialized antibodies against latent
membrane protein (LMP) 1 detected by conventional IHC
and against Epstein–Barr nuclear antigen (EBNA) 2 detected
by immunoﬂuorescence, but these methods have relatively
low detection sensitivity and accuracy. In contrast, identifying
Epstein-Barr–encoded RNAs (EBERs) by ISH facilitates viral
detection with high sensitivity and speciﬁcity and allows the
visualization of viral RNA in the nucleus of tumor cells. At
the present time, there are commercially available probes that
can be used on parafﬁn-embedded tissue with a permanent
chromogen. Therefore, ISH remains the gold standard for
EBV detection in tissue samples17 (Fig. 4). Western blot, ﬂow
cytometry, and enzyme-linked immunosorbent assay can
potentially detect and measure selected viral proteins for
which antibodies are available. However, the single
most informative protein-based assay is ISH because it per-
mits localization of protein in the context of histopathology,
facilitating assessment of the medical signiﬁcance of the
infection.29 Localization is achievable in parafﬁn-embedded
sections for latent and lytic viral factors, including EBNA1,
EBNA2, LMP1, LMP2, BHRF1, BZLF1, and BRLF1.30
Interpretation of results, deﬁning the spectrum of expressed
genes and their localization to benign- or malignant-appearing
cells, complements EBER ISH for diagnosis of EBV-related
disease.31 Immunostaining with EBV-LMP yields a cytoplas-
mic pattern.12 This marker is useful in the diagnosis of
posttransplant lymphoproliferative disorders, Hodgkin lym-
phoma, and other lymphomas. It is also positive in 25%–
50% of nasopharyngeal carcinomas.12 LMP1 immunostain
(cytoplasmic and membranous localization) has been shown
to be nearly as effective as EBER ISH in identifying EBV in
lymph nodes of patients with infectious mononucleosis.
Likewise, BZLF1 (characterizes lytic viral replication)
immunostains (nuclear staining) have been shown to be
useful in conﬁrming diagnosis of oral hairy leukoplakia in
tongue biopsies of AIDS patients.32
Technical problems can foil interpretation of immuno-
histochemical results. For example, EBNA1 is thought to be
expressed in virtually all latently infected tumors; yet, EBNA1
FIGURE 4. Histopathologic and ISH
findings in a patient with hairy leu-
koplakia and AIDS. A, Irregular epi-
thelial hyperplasia with ballooning
of the keratinocytes of the upper
layers. B, Higher magnification
showing large pale-staining cells in
the upper layers of the epithelium
with irregular wrinkled nuclei. Note
the presence of some intranuclear
inclusion bodies. C, The same case
studied by ISH for EBER. D, Many
nuclei of the keratinocytes of the
upper layers show EBER positivity.
(A and B, hematoxylin–eosin stain;
C and D, ISH for EBER. Original
magnifications: A, ·10; B, ·400;
C, ·10, D, ·400.)
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IHC is not sensitive enough to reliably substitute for EBER
ISH. Furthermore, the 2B4 clone of EBNA1 antibody cross-
reacts with human MAGEA4, potentially causing false-
positive interpretations.33 Problems such as these emphasize
the need to validate laboratory assays before they are used in
clinical investigations.
Cytomegalovirus
CMV belongs to the subgroup of b-herpesviruses. Like
other members of the family Herpesviridae, this virus produces
primary infection, latent infection, and reinfection; however, its
site of latency is not known. CMV infection is especially com-
mon in immune-compromised patients (such as HIV-infected
patients), and the cutaneous manifestations can be quite vari-
able, including ulcers, vesicles, papules, purpuric macules, ver-
rucous lesions, prurigo nodularis–like lesions, and digital
infarcts. In CMV infections, the characteristic observations
are made in the endothelial cells of dermal blood vessels.
The nuclei of these cells have large eosinophilic inclusions
surrounded by a clear halo.34 Less frequently, inclusions sim-
ilar to those found in the nuclei of endothelial cells have also
been described in the nuclei of ﬁbroblasts and macrophages
and also in the nuclei of the epithelial cells of eccrine ducts in
CMV infections.35
CMV skin infection may be difﬁcult to identify by
clinical or histopathologic ﬁndings for various reasons. First,
cutaneous CMV is rare, and the paucity of cases does not lend
itself to microscopists having the opportunity to study a large
number of cases. Second, the clinical manifestations of CMV
infection vary, and there are no speciﬁc clinical ﬁndings that
allow a clinician to suspect the right diagnosis. Third, the
histopathologic ﬁndings of cutaneous CMV are typically
present in scattered cells, and often, only a few cells have
cytopathologic changes.35,36 Therefore, immunohistochemical
analysis may be needed to conﬁrm the diagnosis in the setting
of intense inﬂammation or in cases where only few cells are
infected35 (Fig. 5). IHC allows for rapid diagnosis; its sensi-
tivity is higher than that of light microscopy and is compara-
ble with that of culture and ISH.
Immunostaining with monoclonal anti-CMV antibody
by immunoperoxidase methods gives a nuclear staining pattern
in early-stage infections and a nuclear and cytoplasmic pattern
in late-stage infections.12 The anti-CMV antibody is known to
bind with great avidity to CMV antigen synthesized in both
early and late stages of infection.37
Human Herpesviruses 6 and 7
HHV-6 and HHV-7 are ubiquitous and have been
associated with several cutaneous diseases, including roseola
infantum, infectious mononucleosis, Rosai–Dorfman disease,
pityriasis rosea, lichen planus, hypersensitivity reactions,
graft-versus-host disease, and several other cutaneous mani-
festations, including various malignancies.38 HHV-6 consists
of 2 closely related yet distinct viruses, designated HHV-6
variant A and HHV-6 variant B. HHV-6 variant B is the
etiological agent of the common childhood illness exanthema
subitum, also known as roseola infantum or sixth disease of
childhood. In adults, infection is seen primarily in immuno-
compromised individuals. In immunocompetent patients, the
FIGURE 5. Histopathologic and
immunohistochemical findings in the
border of a perianal ulcer in a HIV-
infected patient. A, Scanning power
showing discrete perivascular in-
filtrates in superficial dermis and
around eccrine units. B, Higher
magnification demonstrated that the
nuclei of some endothelial cells and
perivascular cells contained large
eosinophilic inclusions surrounded
by a clear halo. C, The same case
immunohistochemically studied for
CMV. D, Immunoexpression for CMV
in the cells containing eosinophilic
inclusions in their nuclei. (A and B,
hematoxylin–eosin stain; C and D,
IHC for CMV. Original magnifica-
tions: A, ·10; B, ·400; C, ·10;
D, ·400.)
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infection is usually diagnosed on the basis of its clinical
features. However, the diagnosis in immunocompromised
patients may need additional laboratory methods, including
viral culture, serologic testing, polymerase chain reaction
(PCR) assay, and tissue biopsy.38 The histopathologic ﬁnd-
ings of HHV-6 and HHV-7 cutaneous infections are nonspe-
ciﬁc. Epidermal spongiosis, some degree of vacuolar
degeneration of the basal layer of the epidermis, and a super-
ﬁcial perivascular lymphocytic inﬁltrate may be observed.9
Immunohistochemical detection of HHV-6 and HHV-7
in skin biopsies is not commonly performed in routine clinical
practice. However, several studies have reported positive
results in the course of different clinical settings. Sumiyoshi
et al39 reported positive immunohistochemical staining with
the HHV-6–speciﬁc monoclonal antibodies OHV-1 and
OHV-2, using the avidin–biotin alkaline phosphatase
method, in skin biopsy specimens from patients with pri-
mary HHV-6 infection and erythroderma. They found pos-
itive staining in the lymphocytes infected with HHV-6 in the
skin.39 Yadav et al40 also reported the detection of HHV-6–
associated antigens in formalin-ﬁxed and parafﬁn-embedded
oral tissues from patients with lichen planus, leukoplakia,
and squamous cell carcinoma. They used the mouse
(6A5G3) monoclonal antibody to the HHV-6 gp116/64/
54 KDa component, which is a late protein in the viral
replicative cycle. Furthermore, Broccolo et al41 reported
the immunohistochemical detection of the HHV-7 pp85
and the HHV-6 p41 antigens in skin biopsy specimens of
patients with pityriasis rosea (17% and 67% of patients
analyzed, respectively), suggesting that they might play
an etiological role in this disease. HHV-7 and HHV-6
antigen-positive cells were located mainly in the
perifollicular and papillary dermis, with the exception of
1 patient in whom HHV-7 pp85 was also found in the
epidermal cells.
Human Herpesvirus 8
HHV-8 has been shown to be involved in the develop-
ment of all the epidemiologic variants of KS. This involvement
was demonstrated in 1994 when unique DNA sequences were
isolated from biopsies of KS.42 The virus, initially called
KS-associated herpesvirus, was subsequently renamed
HHV-8. HHV-8 infects the endothelial-derived spindle cells
of KS and CD19+ B cells. This latter event may be etiolog-
ically signiﬁcant in the causation of some cases of multicen-
tric Castleman disease and primary effusion lymphoma.43 It
has also been found in lymphomas and in other lymphopro-
liferative disorders with heterogeneous presentations.44 Its
presence in a number of skin cancers and in lesions of pem-
phigus vulgaris and pemphigus foliaceus has not been satis-
factorily explained, although tropism for lesional skin has
been postulated.45,46
HHV-8 can be detected by PCR in parafﬁn-embedded
tissue, although the viral load seems to be low.47,48 It is much
easier to perform IHC using the commercially available mono-
clonal antibody against HHV-8 that is directed against the
C-terminus of the latent nuclear antigen-1 (LNA-1) encoded
by the ORF-73 gene.49 The presence of HHV-8 in the nuclei of
proliferating cells in KS lesions may be demonstrated in all its
epidemiologic variants and from the earliest phases of the pro-
cess. It is largely conﬁned to the spindle cells in the nodular
phase (Fig. 6), but it is found in the endothelial cells of the slit-
like vessels in the early patch and plaque stages.
FIGURE 6. Histopathologic and
immunohistochemical findings in
a nodular lesion of an elderly male
with classic KS. A, Scanning power
showing a well-circumscribed dermal
nodule. B, Higher magnification
demonstrated short fascicles of spin-
dled or rounded cells (depending on
the cut plane) and small spaces filled
by red cells. C, The same case im-
munohistochemically studied for
HHV-8. D, Immunoexpression for
HHV-8 in most of the nuclei of spin-
dled cells. (A and B, hematoxylin–
eosin stain; C and D, IHC for HHV-8.
Original magnifications: A, ·10;
B, ·400; C, ·10; D ·400.)
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HHV-8 has both a lytic and latent phase of replication.
During the latent phase, viral DNA copies are maintained as
episomes attached to the host chromosome with the help of
LNA-1.50 This explains why LNA-1 immunoreactivity in KS
cells most often appears as stippled nuclear staining. Most
cells in KS lesions and HHV-8–infected cell cultures are
latently infected. In only a small percentage (,5%) of in-
fected cells is lytic HHV-8 replication seen.51 This is clearly
helpful for diagnostic purposes because most KS lesional
cells will accordingly be LNA-1 immunoreactive.
Given the strong association between HHV-8 infection
and KS, positive immunoreactivity for LNA-1 has proved to
be the most useful diagnostic marker to help differentiate
KS from its mimickers, including angiosarcoma, kaposiform
hemangioendothelioma, spindle cell hemangioma, and benign
lymphangioendothelioma, among others.52,53 However,
a minority of conventional angiosarcomas (29%) were found
to be HHV-8 positive,54 whereas no HHV-8 expression could
be observed in radiation-related angiosarcomas.55 LNA-1 IHC
is favored over PCR (for HHV-8) for the evaluation of prob-
lematic vascular proliferations in patients infected with HIV.
LNA-1 is a highly sensitive and speciﬁc immunohistochem-
ical marker for KS in both the general (HIV negative) pop-
ulation and HIV-positive patients.56 HHV-8 immunoreactivity
seems to be unaffected by HIV status, patient age, gender,
tumor recurrence, or the site of the KS lesion.49
Immunostaining KS with LNA-1 for diagnostic pur-
poses is especially useful for the following: (1) Early subtle
patch-stage lesions in which the histopathologic ﬁndings are
not immediately obvious and may be difﬁcult to diagnose on
tissue biopsy. In these cases, inﬂammatory processes are the
main differential diagnosis to be considered, stasis derma-
titis being the most important. Other histopathologic alter-
ations, such as ulceration, lymphedema, and secondary
infections, may obscure the histopathologic characteristic
of KS, rendering viral detection crucial for the diagnosis. (2)
KS lesions that mimic other conditions, like pyogenic
granuloma–like and angiomatous variants of KS. These his-
topathologic variants of KS are characterized by the prolif-
eration of well-formed capillaries organized in lobules and
surrounded by epidermal collarets, with no solid aggregates
of fusiform cells, and they mimic benign vascular prolifer-
ations with a lobular capillary hemangioma pattern.50 (3) KS
presenting in unusual locations. (4) Histopathologic differ-
ential diagnosis with other vascular proliferations mimicking
KS, such as hobnail hemangioma, spindle cell hemangioma,
benign lymphangioendothelioma, and kaposiform heman-
gioendothelioma. The presence of HHV-8, however, seems
not to be fully restricted to KS, as HHV-8 has been detected
(albeit rarely) in some angiosarcomas, hemangiomas, and
dermatoﬁbromas,57 although the meaning of this ﬁnding re-
mains uncertain. Finally, the immunohistochemical demon-
stration of HHV-8 DNA may be a useful adjunct in the
diagnosis of KS by ﬁne-needle aspiration.58
PAPILLOMAVIRUSES
Papillomaviruses are DNA viruses, which replicate in
the nucleus. The only important virus in this group in
dermatopathology is the human papillomavirus (HPV),
which produces various types of warts on different areas
of the skin.59 Several phylogenetic groups may be
distinguished among the more than 150 known HPV types.
Group A HPV types, occurring on genitals and mucous
membranes, and cutaneous group B beta HPV, also associ-
ated with epidermodysplasia verruciformis, are of greatest
signiﬁcance for dermatologists.
The diagnosis of HPV-associated benign and malig-
nant epithelial lesions is predominantly based on clinical
features and conventional histopathology. Two of the most
speciﬁc histopathologic ﬁndings are the presence of koilo-
cytosis, which is not invariable, especially in long-standing
warts, and the so-called koilocytotic atypia, mostly seen at
the granular layer, which consists of nuclear variation in size
and staining pattern, with irregularity of nuclear membrane
and binucleated or multinucleated cells.60 With only few
exceptions (HPV types 4 and 63 with ﬁlamentous inclusion
bodies61 and HPV type 60 with eosinophilic intracytoplas-
mic large granules62), histology does not grant exact speci-
ﬁcation of the HPV type involved.9 Papillomavirus antigen
can be detected by immunoperoxidase methods.63 Immuno-
histochemical detection of the HPV L1 capsid antigen
(Fig. 7) is indicative of replicative HPV infections, but this
method does not facilitate identiﬁcation of the virus type
involved, either. HPV antigens are detected in 64% of acan-
thopapillomas with koilocytes, but not in any lesion without
histologic evidence for koilocytes, thus indicating that IHC
is only of limited value.64
The use of new techniques, such as DNA hybridization,
has allowed the separation of more than 120 antigenically
distinct strains of HPV.65,66 Further genotypes have been
identiﬁed, but not fully characterized. PCR is now used rou-
tinely for the typing of HPV.67 In recent years, attempts have
been made to relate speciﬁc antigenic strains of HPV to par-
ticular clinicopathologic groups of verrucae.68,69
In the ﬁeld of cervical cancer, the identiﬁcation of
HPV-related precancer that is likely to progress to an
invasive carcinoma is very important. Although cervical
cancer screening relies on cervical cytology and high-risk
HPV detection, the histologic diagnosis, and speciﬁcally
lesion grade, is the main parameter that drives clinical
management of screen-positive women. Morphologically
diagnosed squamous intraepithelial lesions regress sponta-
neously in more than half of the cases, but identifying those
likely to persist and progress is not currently possible based
on morphology. It has been suggested that patterns of viral
protein expression may be used to differentiate between self-
limited productive viral infection and a true precancer.70
Some studies have evaluated the immunohistochemical
expression of HPV capsid proteins L1 and L2 in squamous
intraepithelial lesions as a predictive tool for progression.71
Lack of major capsid protein L1 expression has been sug-
gested as a feature in progressive lesions, whereas expres-
sion of the minor capsid protein L2 has not been extensively
evaluated.
Recently, Wititsuwannakul et al72 have evaluated the
sensitivity and speciﬁcity of a commercially available anti-
HPV antibody (BPV-1/1H8 + CAMVIR, ab 2417, Abcam),
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which detects HPV types 1, 6, 11, 16, 18, and 31 in formalin-
ﬁxed parafﬁn-embedded tissue, in 25 lesions (both HPV
induced and non-HPV induced) mostly from the genital region,
compared with ISH and hematoxylin and eosin staining. They
found a sensitivity and speciﬁcity for this anti-HPV antibody of
90.9% and 85.7%, respectively, compared with ISH. IHC, like
ISH, was generally positive in cases showing koilocytes/koilo-
cytotic atypia (86%). However, IHC also detected productive
infection with HPV in 23% (3 of 13) of cases without koilo-
cytes/koilocytotic atypia. Positive immunostaining is mostly
seen in corneocytes, the nuclei of the keratinocytes of the
granular layer, and upper layers of the epidermis (Fig. 8). A
FIGURE 7. Histopathologic and
immunohistochemical findings in
a genital wart from an otherwise
healthy young adult male. A, Scanning
power showing a regular acanthosis of
the epithelium. B, Higher magnifica-
tion showed prominent koilocytosis in
the upper layers of the epithelium. C,
The same case immunohistochemi-
cally studied for HPV L1 capsid anti-
gen. D, Immunoexpression for HPV L1
is seen in many nuclei of the kerati-
nocytes of the upper layers. (A and B,
hematoxylin–eosin stain; C and D, IHC
for HPV L1. Original magnifications:
A, ·10; B, ·400; C, ·10; D, ·400.)
FIGURE 8. Histopathologic and
immunohistochemical findings in
a genital wart from a young adult
woman with history of persistent
condyloma acuminatum involving
the vulva. A, Scanning power of
a shave biopsy showed a thick
compact orthokeratotic horny layer.
B, Higher magnification showed
some koilocytes in the upper layers
of the horny layer. C, The same
case immunohistochemically studied
with CAMVIR antibody. D, Im-
munoexpression for HPV in many
nuclei of the corneocytes of the
upper layers with CAMVIR antibody.
(A and B, hematoxylin–eosin stain; C
and D, IHC for CAMVIR antibody.
Original magnifications: A, ·10;
B, ·400; C, ·10; D, ·400.)
Am J Dermatopathol  Volume 37, Number 1, January 2015 Cutaneous Viral Infections
 2015 Lippincott Williams & Wilkins www.amjdermatopathology.com | 9
major disadvantage of IHC, compared with ISH and PCR, is its
inability to type HPV. But IHC shows considerable advantages
over ISH and PCR, such as the low cost, rapid turnaround time,
and the ability to visualize productive HPV infection in tissue
sections.72 Because results of IHC for HPV with this antibody
correlate with ISH, both tests are very helpful to conﬁrm HPV
infection (IHC) and subsequent HPV typing (ISH).
In conclusion, this review is focused on the use of IHC
to identify viral pathogens that are relevant to dermatopathol-
ogy and on the usefulness of these techniques in the diagnosis
of cutaneous viral infections and other related diseases.
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Upon completion of this learning activity, participants should be better able to use immunohistochemistry (IHC) to
identify viral pathogens that are relevant to dermatopathology and apply these techniques in the diagnosis of cutaneous viral
infections and other related diseases.
1. In cutaneous infections due to Herpes simplex virus, the strongest immunohistochemical staining is seen in the:
a. Lymphocytes of the inﬂammatory inﬁltrate
b. Apocrine glands epithelium
c. Eccrine glands epithelium
d. Outer root sheath of the hair follicle
e. Epidermal keratinocytes
2. In cutaneous early infections due to Varicella-zoster virus, the strongest immunohistochemical staining is seen in the:
a. Outer root sheath of the hair follicle
b. Sebocytes of the sebaceous gland
c. Epidermal keratinocytes
d. Nerves of the dermis
e. a and b
3. Epstein–Barr virus has been related to all the following diseases, except:
a. Infectious mononucleosis
b. Hairy leukoplakia in patients with AIDS
c. Nasopharyngeal lymphoepithelial carcinoma
d. Lymphoproliferative disorders
e. Epidermodysplasia verruciformis
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4. In Kaposi’s sarcoma, with which of the following monoclonal antibodies will most lesional cells be immunoreactive?
a. LNA-1
b. VZV
c. CM5E1
d. Ab3
e. LMP1
5. In which of the following viral-related skin diseases are the histopathological ﬁndings not speciﬁc?
a. Trichodysplasia spinulosa
b. Kaposi’s sarcoma
c. Exanthema subitum
d. Orf
e. Merkel cell carcinoma
6. Which of the following HPV-immunohistochemical staining patterns has been suggested as a feature indicating progression
in the ﬁeld of cervical cancer?
a. Positive HPV-cytoplasmic immunoexpression
b. Lack of expression of major capsid protein L1
c. Lack of expression of major capsid protein L2
d. Expression of the minor capsid protein L2
e. Lack of expression of major and minor capsid proteins
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CME ARTICLE
Immunohistochemistry in the Diagnosis of Cutaneous Viral
Infections- Part II: Cutaneous Viral Infections by
Parvoviruses, Poxviruses, Paramyxoviridae, Picornaviridae,
Retroviruses and Filoviruses
Ana M. Molina-Ruiz, MD,* Carlos Santonja, MD,† Arno Rütten, MD,‡ Lorenzo Cerroni, MD,§
Heinz Kutzner, MD,‡ and Luis Requena, MD*
Background: Cutaneous viral infections are increasing in recent
years, particularly in immunocompromised patients.
Objective: Immunohistochemistry (IHC) provides a rapid and
helpful tool that can be applied to conﬁrm the diagnosis of speciﬁc
viral infections that may be difﬁcult to diagnose with certainty using
routine microscopy alone.
Methods: Several immunostains that are useful in histopathology
have been reviewed and tested in cutaneous samples of viral
infections. Emphasis is placed on new stains and novel uses of
existing stains.
Results: This article is an up-to-date overview of the potential uses
of IHC in the histopathologic diagnosis of cutaneous viral infections
by parvoviruses, polyomaviruses, poxviruses, paramyxoviridae,
picornaviridae, retroviruses, and ﬁloviruses.
Limitations: Speciﬁc monoclonal antibodies are commercially
available only for some members of these virus families.
Conclusions: IHC may assist dermatopathologists to appropriately
diagnose viral infections by parvoviruses, polyomaviruses, poxvi-
ruses, paramyxoviridae, picornaviridae, retroviruses, and ﬁloviruses.
Key Words: immunohistochemistry, virus, skin, infection, parvovi-
ruses, polyomaviruses, poxviruses, paramyxoviridae, picornaviridae,
retroviruses, ﬁloviruses
(Am J Dermatopathol 2015;37:93–106)
LEARNING OBJECTIVES
Upon completion of this learning activity, participants
should be better able to:
1. Use immunohistochemistry (IHC) to identify viral patho-
gens that are relevant to dermatopathology.
2. Apply these techniques in the diagnosis of cutaneous viral
infections and other related diseases.
INTRODUCTION
In this part II of this review, we highlight the available
main immunohistochemical techniques that have been used and
continue to evolve in the diagnosis of mucocutaneous in-
fections caused by parvoviruses, polyomaviruses, poxviruses,
paramyxoviridae, picornaviridae, retroviruses, and ﬁloviruses.
MATERIALS AND METHODS
The biopsy specimens were ﬁxed in 10% buffered
formalin and embedded in parafﬁn. For routine histology,
5-mm-thick sections were stained with hematoxylin and eosin.
Immunohistochemical stains were performed both at the Pathol-
ogy Department of Fundación Jiménez Díaz University Hospital
in Madrid and the Dermatopathology Laboratory at Friedrichsha-
fen, Germany. Tissue sections were processed on a BioTek Sol-
utions TechMate 500 (Dako), where 1-hour incubation with
a primary antibody was performed. The immunohistochemical
study of the viral pathogens was performed using the commer-
cially available antibodies. Several antibodies for speciﬁc viruses
described in the literature were not commercially available at the
time of elaboration of this manuscript; therefore, immunohisto-
chemical staining for these pathogens could not be tested.
PARVOVIRUSES
The Parvoviruses are single-stranded DNA viruses and
among the smallest known DNA-containing viruses to infect
mammalian cells. Parvovirus B19 (PVB19), which belongs to
the genus Erythrovirus, is the only known human pathogen in
this family.1 Primary infection with PVB19 can be either
asymptomatic or bring about a number of clinical syndromes.
These include 2 speciﬁc PVB19-related dermatologic dis-
eases, erythema infectiosum (ﬁfth disease), and purpuric
“gloves-and-socks” syndrome (PPGSS). The most frequently
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observed dermatological manifestation of PVB19 infection is
erythema infectiosum, while PPGSS is rare, and less than 100
cases have been reported.2 The histopathologic ﬁndings in
infectious erythema and PPGSS are nonspeciﬁc, and usually
consist of foci of epidermal spongiosis, with a superﬁcial
perivascular inﬁltrate mostly composed of lymphocytes and
some extravasated red cells.2
Demonstration of viral DNA in serum and/or skin biopsy
samples has been carried out in a handful of reports as a means of
linking PPGSS to PVB19 infection.3–5 However, it has become
clear that PVB19 can persist for a long time in human tissues,6
and viral DNA has been found in normal skin with a frequency
ranging from 22.5% to 76%.7,8 This raises the issue whether
PVB19 should be regarded as a true pathogen or as an innocent
bystander. However, PVB19 can be detected immunohistochemi-
cally in the cytoplasm of endothelial cells of congested capillaries
in the papillary dermis in skin lesions in PPGSS (Fig. 1) and
infectious erythema using the anti-PVB19 monoclonal antibody
directed against the viral protein VP2.2,9,10 Therefore, immuno-
histochemical detection of PVB19 in the endothelial cells of
biopsy specimens performed in the clinical setting of PPGSS
and other related exanthemas could be pathogenetically signiﬁ-
cant and help in the understanding of these diseases.
PVB19 infects cells possessing the receptor for viral
entry, the P blood group antigen globoside, with help from
coreceptors alpha5beta1 integrin and Ku80.11 The distribution
of viral receptors in different tissues (erythroid progenitors,
endothelium, megakaryocytes, fetal myocytes, liver, lung,
kidney, synovium, and placental trophoblast) plays a signiﬁ-
cant role in the pathogenesis of the most frequent syndromes
related to PVB19 infection, which include transient aplastic
crises, anemia, fetal hydrops, ﬁfth disease, PPGSS, and
arthropathy. Santonja et al2 demonstrated PVB19 endothelial
positivity in several cases of PPGSS and proposed that the
immunohistochemical detection of PVB19 in the endothelial
cells of PPGSS suggests that PVB19 triggers an immunologic
response responsible for the histopathologic ﬁndings of peri-
vascular lymphocytic inﬂammation/lymphocytic vasculitis,
edema, and red blood cell extravasation.2 Moreover, involve-
ment of the endothelium by PVB19 is in keeping with the
expression of the viral receptor globoside by endothelial cells
and suggests that the exanthema results from a cytotoxic
T-cell reaction to virally infected cells. Other authors9,10 have
found PVB19 positive labeling not only of the endothelial
cells of the dermal vessels but also of the epithelium of
eccrine glands, ducts, and epidermal keratinocytes in biopsy
specimens of PPGSS.
Endothelial cell involvement by the virus has also been
investigated by PVB19 RNA expression in endothelium, by
reverse transcriptase in situ polymerase chain reaction (PCR) and
by immunohistochemistry (IHC) in the context of vasculitis and
autoimmune diseases.12 The subsequent immunologic reaction
has been linked not only with dermatologic conditions (including
scleroderma, adult Schönlein purpura, and dermatomyositis)13–15
but also with systemic diseases, such as systemic lupus erythe-
matosus, myocarditis, and pulmonary ﬁbrosis.16–18
POLYOMAVIRUSES
Polyomavirus (PyV) infections were accidentally dis-
covered in the 1950s when characterizing a transmissible agent
causing multiple tumors in rodents, hence providing the name
(Greek poly-multiple; -oma, tumors).19 Today the expanding
family of human PyV (HPyV) consists of 10 members, but
only 2 of them are important for dermatopathologists: the
recently identiﬁed Merkel cell polyomavirus (MCPyV) and
trichodysplasia spinulosa polyomavirus (TSPyV). Serological
FIGURE 1. Histopathologic and immu-
nohistochemical findings in the cuta-
neous lesions of a patient with PPGSS.
A, Scanning power showing discrete
perivascular infiltrates in the superfi-
cial dermis. B, Higher magnification
demonstrated perivascular lympho-
cytes and extravasated red cells. C,
The same case immunohistochemi-
cally studied with the anti-PVB19
monoclonal antibody directed
against the viral protein VP2. D, Im-
munoexpression for PVB19 within the
cytoplasm of endothelial cells (A and
B, hematoxylin–eosin stain; C and D,
IHC for PVB19 antibody; original
magnifications: A ·10, B ·400, C
·10, and D ·400).
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studies suggest that HPyVs subclinically infect the general
population with rates ranging from 35% to 90%. However,
signiﬁcant disease is only observed in patients with impaired
immune functions.20
Merkel Cell Polyomavirus
Merkel cell carcinoma (MCC) is a rare but aggressive
human skin cancer that typically affects elderly and immuno-
suppressed individuals, a feature suggestive of an infectious
origin. The search for an infectious agent yielded a major
breakthrough in 2008; the discovery of the MCPyV by means
of digital transcriptome subtraction.21 Numerous studies rap-
idly validated the association of MCC with this virus that is
integrated in the nuclei of MCC neoplastic cells.22–24 Although
the association between MCC and the MCPyV is now well
established, it is also clear that this virus is not required for
MCC as approximately 20% of these tumors contain no detect-
able MCPyV. Moreover, it is clear that MCPyV is not sufﬁ-
cient for developing MCC because it remains a rare cancer
despite the fact that more than half of adults have antibodies
to MCPyV and hence were exposed to the virus, typically in
childhood.24,25 Finally, MCPyV is not exclusive to MCC
because it has also been observed rarely in certain squamous
cell carcinomas in immunosuppressed patients.26,27
Since the original report, multiple studies have dem-
onstrated the clonal integration of MCPyV in the nucleus of
MCC cells in approximately 80% of the cases. A variety of
methods have been used to detect the presence of the virus,
including Southern blot analysis, PCR ampliﬁcation of
viral DNA, detection of integrated PyV sequences, in situ
hybridization, DNA sequencing by hybrid capture, RT-PCR,
and IHC with antibodies speciﬁc for MCPyV large T antigen
and small T antigen.24,28–30 Based on homology to other
polyomaviruses, the MCPyV large and small T antigens
are predicted to be oncogenic and contribute directly to
the carcinogenesis of MCC.30
Shuda et al29 developed a monoclonal antibody
CM2B4 against a peptide fragment of the MCPyV T antigen
exon 2 to detect MCPyV oncoprotein expression in the
MCC tumor cells directly. The majority of the CM2B4-
positive tumors showed strong and diffuse nuclear labeling
in a large part of the tumor cell population (Fig. 2) and 77%
of the PCR-positive tumors were immunoreactive for
CM2B4. Later, these same authors31 reported that the
CM2B4 antibody failed to detect large T antigen in several
cases of MCC but that many of these negative specimens
stained positive with the monoclonal antibody CM5E1 speciﬁc
for MCPyV small T antigen. The combined use of CM2B4 and
CM5E1 led to detection of MCPyV T antigens in 47 (92%) of
51 cases of MCC, whereas CM2B4 alone detected large
T antigen in 75% of cases.
Recently, Rodig et al30 have performed IHC staining
with a newly developed mouse monoclonal antibody, Ab3, that
has markedly increased sensitivity in detecting MCPyV large T
antigen (97%) in MCC compared with CM2B4 (80%). They
propose that the presence of MCPyV in MCC is more common
than previously reported and that improved detection methods
may reveal that practically all MCC specimens contain viral
DNA of MCPyV. Ab3 does not stain lymphocytes, even when
used at higher concentrations or when staining tonsillar and
reactive lymph node tissue specimens. The lack of nonspeciﬁc
staining may be especially useful in clinical specimens because
MCC tumors frequently contain inﬁltrating lymphocytes.32
Furthermore, Ab3 did not stain tumor specimens from
gastrointestinal neuroendocrine tumors or small cell lung can-
cer, supporting its usefulness as a clinical biomarker for MCC.
FIGURE 2. Histopathologic and immu-
nohistochemical findings in a MCC. A,
Scanning power showing a neoplasm
that involved the full thickness of the
dermis and extended to subcutaneous
tissue. B, Higher magnification dem-
onstrated that the tumor was com-
posed of small round cells with
vesicular nuclei and multiple small
nucleoli. C, The same case im-
munohistochemically studied with the
monoclonal antibody CM2B4 against
a peptide fragment of the MCPyV. D,
Immunoexpression for CM2B4 is seen
in the nuclei of neoplastic cells (A and
B, hematoxylin–eosin stain; C and D,
IHC for CM2B4 antibody; original
magnifications: A ·10, B ·400, C ·10,
and D ·400).
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Several studies26,27 have shown that MCPyV DNA may
be identiﬁed by PCR in up to 70% of nonmelanocytic cutaneous
neoplasms in immunocompetent and immunosuppressed
patients. Unlike MCC, these skin tumors exhibit no immu-
nohistochemical evidence for intracellular viral antigens.
Inﬂammatory cells may have transported viral DNA into
peritumoral inﬁltrates as suggested by the fact that inﬂam-
matory CD14+ CD162 monocytes constitute a reservoir for
MCPyV.33 When interpreting MCPyV detection, it is there-
fore essential to consider both molecular biology and
immunohistochemical results.
Trichodysplasia Spinulosa Polyomavirus
Trichodysplasia spinulosa (TS) is a folliculocentric skin
disorder that presents as keratotic spiny papules typically
distributed over the ears and structures of the central face and
less commonly involves the extremities, trunk, and scalp.
Alopecia, usually most severely affecting the eyebrows and
eyelashes, often accompanies the disorder. Haycox et al34, in
1999, were the ﬁrst authors using the term TS to describe friable
follicular spinous lesions in a patient who received a combined
renal/pancreas transplant. The authors showed, for the ﬁrst time,
the intracellular presence of virus particles with an appearance
that was interpreted by them as consistent with viral particles of
the Papovaviridae family. However, the original description of
this disorder was published by Izakovic et al, in 1995, when
they reported hair-like hyperkeratosis in patients with kidney
transplants and considered the process as a new cyclosporine
side-effect.35 Since then, several cases have been reported in
the literature20,36–67 under different names, including viral-
associated trichodysplasia,39,43,49,52,60 trichodysplasia of immu-
nosuppression,45 virus-associated TS,40 follicular dystrophy
of immunosuppression,37 cyclosporine-induced folliculodystro-
phy,38 pilomatrix dysplasia,36 and spiny hyperkeratosis
(hair-like hyperkeratosis).41 In 2010, van der Meijden et al46
identiﬁed a new HPyV (TSPyV) in plucked facial spines of
a heart transplant patient with TS, conﬁrming the PyV etiology
of this process.
The histopathologic ﬁndings are distinctive and consist of
distorted and dilated anagen hair follicles ﬁlled by sheets of
eosinophilic cells exhibiting the appearance of inner root sheath
cells.34,35 These cells, which contain abnormally large trichohya-
line granules, abruptly cornify without the presence of a granular
cell layer. The involved follicles, instead of the full keratinization
toward a mature hair shaft, appear replete with sheets of nucleated
cornifying cells that persist throughout most of the lower segment
of the hair follicles. The observation was made that pathogenesis
seemed to be related to immunosuppression, with the lesions
resolving as immune function returned to normal.
Several tools, including scanning electron microscopy,
PCR analysis of viral DNA, or immunohistochemical staining
for the PyV middle T antigen, have been used to identify the
pathogenic virus associated with TS. In the initial description of
viral-associated TS, immunohistochemical stains demonstrated
increased Ki-67 protein expression and negative staining for
Papillomavirus.34 At that time, the initial virus was assumed to be
part of the Papovaviridae family, which has subsequently been
split into the Papillomaviridae and Polyomaviridae families.
Most studies in TS have identiﬁed TSPyV by electron
microscopy,39,40,42,43,49,54,55,57 PCR studies,20,49,54,55,57,59,66 or
immunoﬂuorescence,54 but very few attempts have been per-
formed by IHC.55,60 In the case described by Fischer et al,55
immunohistochemical investigation for the HPyV middle T anti-
gen with the SV40 antibody, which recognized the NH2 termi-
nus within amino acids 83–128 of a large tumor antigen of SV-
40 and JCV of PyVs, failed to detect the virus in lesional skin,
renal allograft, and urine specimens.55 However, Wanat et al60
have recently described immunohistochemical positivity with
SV-40 antibody for TSPyV in lesional skin of a patient with
TS, demonstrating positive staining of the large eosinophilic
cellular inclusions within keratinocytes composing the inner root
sheath in all the follicles examined in the patient’s samples, and
we have corroborated these ﬁndings (Fig. 3). These positive
cellular inclusions are visualized on both vertical and horizontal
sections, and scanning electron microscopy conﬁrmed that these
inclusions contained small, icosahedral, regularly spaced, intra-
cellular viral particles consistent with PyV.60 These authors sup-
port that immunohistochemical staining for the middle T
antigen or other viral proteins may be a useful tool for the
identiﬁcation of this disease process and a potentially more use-
ful and practical way to establish the diagnosis compared with
PCR assay or electron microscopy.60 However, further cases are
required to verify the utility of immunohistochemical staining
because a negative result would not exclude the diagnosis.
Finally, routine testing with PCR assay, electron micros-
copy, or immunohistochemical stains is not necessary in all
cases because routine histologic staining can be sufﬁcient to
make the diagnosis in cases of classic clinical presentations.
Because the true incidence and clinical spectrum of this
recently recognized disease is not known, these tools may be
valuable in conﬁrming the diagnosis in cases involving more
subtle or atypical presentations. It is important that clinicians
are aware of all the potential evaluations that can be performed
and that they recognize the newly described HPyV as the
infectious agent that is responsible for TS.
POXVIRUSES
The family Poxviridae is divided into many genera, of
which the genus Orthopoxvirus includes vaccinia virus, variola
virus, cowpox virus, and at least 6 other species, including mon-
keypox virus, camelpox virus, and raccoonpox virus.68,69 Only 3
other genera cause human disease: the genus Parapoxvirus caus-
ing milker’s nodule, orf, and sealpox69–71; the genus/subgenus
Molluscipoxvirus resulting in molluscum contagiosum72; and the
genus Yatapoxvirus resulting in tanapox. Skin infections caused
by parapoxvirus have characteristic histopathology.
Orf (Ecthyma Contagiosum)
Orf (ecthyma contagiosum) is primarily a disease of
young sheep and goats, involving the lips and perioral area.1 It
is caused by a poxvirus of the paravaccinia subgroup. Orf can
be transmitted to humans by contact with infected animals.
Lesions, which measure approximately 1–3 cm or more in
diameter, develop most commonly on the hands and forearms.
Spontaneous regression is usual approximately in 7–8 weeks.1
The diagnosis is based on case history (contact with
infected animals) and clinical features.73 Viral cultures,
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histopathologic examination of biopsy specimens, electron
microscopy, ﬂuorescent antibody tests, and identiﬁcation of spe-
ciﬁc viral nucleic acid have all contributed to establish the diag-
nosis.73–76 Orf has a distinctive histological appearance of
hyperkeratosis and cell ballooning in the cells of the upper layers
of the epidermis. Eosinophilic intracytoplasmic inclusions are
seen within these ballooned cells. The lesions of orf are generally
regarded as histopathologically indistinguishable from milker’s
nodules,77 although full-thickness epidermal necrosis seems to be
more common in orf. Recently, a monoclonal antibody against
the ORFV059 protein encoded by orf virus have been synthe-
sized, which recognized the ORFV-Jilin ORFV059 protein in
a variety of immunological assays, but to our knowledge, this
antibody is not yet commercially available.78
PARAMYXOVIRIDAE
Measles
Measles is a highly contagious viral disease caused by an
RNA virus of the Paramyxoviridae family, and human beings
are the natural host and reservoir of infection. It spreads through
the respiratory route and the virus tends to involve the lymph
nodes, followed by viremia and infection of any organ,
including the skin.79 The disease is characterized by fever, ma-
laise, cough, nasal congestion, conjunctivitis, and an erythem-
atous maculopapular skin rash that appears 3 or 4 days after the
onset of fever and spreads in a craniocaudal direction becoming
conﬂuent as the disease progresses. A pathognomonic enantem,
named Koplik spots, appears during prodrome and consists of
white papules on the oral mucosa. The disease is largely self-
limiting in immunocompetent and immunized individuals but
may be severe and even deadly in immunocompromised
patients. All countries in the World Health Organization have
renewed their commitment to eliminate measles transmission
by 2015. However, measles has re-emerged in Europe recently
because of suboptimal immunization levels that led to accumu-
lation of susceptible populations over the last years.80
From an histopathologic point of view, the ﬁndings in skin
rash of measles are usually nonspeciﬁc. Examination of the
biopsy specimen usually shows basal vacuolar degeneration and
mild dermal lymphocytic inﬁltrate, which usually is predomi-
nantly perifollicular. In some cases, multiple necrotic keratino-
cytes in the superﬁcial epidermis, multinucleated intraepidermal
cells, and pyknotic keratinocytes in the hair follicle epithelium
have been described.81,82 In the skin and oral mucous lesions
(Koplik’s spots), multinucleated keratinocytes with pyknotic
nuclei have reported in the upper layers of the epithelium,82,83
in the hair follicles,84 and in the acrosyringium,85 and they have
been proposed as a cytopathologic clue for speciﬁc diagnosis.
Intranuclear and intracytoplasmic inclusion bodies and abundant
eosinophils in the inﬁltrate have been also described.86
Electron microscopic, immunoﬂuorescence, and immuno-
histochemical studies have detected the measles virus in lesional
skin within endothelial cells of dermal capillaries,87 epidermal
multinucleate cells,83 dermal ﬁbroblasts and macrophages,87
lymphocytes,84 keratinocytes of the upper layers of the epider-
mis,84,88,89 hair follicles,84,88,90 and sebaceous glands.88 IHC de-
tects the measles virus–speciﬁc antigens with a commercially
available monoclonal antibody directed against the viral nucle-
oprotein90 (Fig. 4). It has also been demonstrated that wild-type
strains of measles virus use the signaling lymphocyte activation
molecule (SLAM, also named CDw150) as a cellular receptor.
In contrast, laboratory strains of measles virus and its derivate
vaccine strains use both SLAM and the complement regulatory
protein CD46 as cellular receptors.91 Immunohistochemical
studies of the skin of measles patients using monoclonal
FIGURE 3. Histopathologic and immu-
nohistochemical findings in cutaneous
lesions of a patient with TS. A, Scan-
ning power showing involvement of
all hair follicles present in the biopsy.
B, Higher magnification demon-
strated that the inner root sheath cells
contained abnormally large tricho-
hyaline granules. C, The same case
immunohistochemically studied with
the monoclonal antibody SV-40 for
TSPyV. D, Immunoexpression for
SV-40 is seen in the large trichohya-
line granules of the inner root sheath
cells (A and B, hematoxylin–eosin
stain; C and D, IHC for SV-40 anti-
body; original magnifications: A ·10,
B ·400, C ·10, and D ·400).
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antibodies anti-SLAM and anti-CD46 have shown that hair fol-
licles, epidermis, capillary blood vessels, ﬁbroblasts, mononu-
clear cells, and acrosyringium were CD46 positive and SLAM
negative.90,92 These results suggest that CD46 may be a receptor
of the wild measles virus in the skin.90,93
PICORNAVIRIADE
Enteroviruses
Enteroviruses comprise a subgroup of Picornaviridae
family that cause a wide spectrum of disorders associated
with exanthemas. The non-polio enteroviruses include echo-
viruses and coxsackie types A and B. These viruses have
a single-stranded RNA genome and an unenveloped capsid.
Enteroviral infections are worldwide infections trans-
mitted by fecal–oral or respiratory route. Enteroviruses ﬁrst
infect epithelial cells of the upper airway or lower alimentary
tract, replicate in lymph nodes, and disseminate by an initial
viremia. Subsequently, replication occurs in many organs and
during this replication period is when clinical manifestations
appear. A second and major viremia occurs during this period
or viral replication occurs in the secondary infection sites.94
Hand-foot-and-mouth disease (HFMD) is the most
characteristic exanthematous disease caused by enteroviruses.
Numerous coxsackie serotypes have been implicated, coxsackie
A16 being the most common etiologic factor. Prodromos
consist of fever and malaise and few days later the exanthema
appears. Dermatologic manifestations are characterized by the
abrupt onset of elongated ovoid small vesicles on the palms and
soles, in conjunction with erosive stomatitis. In rare cases,
vesicles may also involve dorsum of the hands and feet and
other nonacral areas of the skin. Most patients with HFMD have
a benign and self-limited course, although in rare cases of
outbreaks of severe enterovirus 71 infection, cardiopulmonary
and neurologic complications and even death of involved
patients have been described.95
Herpangina is a pediatric febrile disease cause by
coxsackie virus groups A and B or echoviruses characterized
by painful vesicles and erosions in buccal mucosa, soft
palate, and tonsils.96 Enteroviruses may also be the etiologic
agent for the so-called eruptive pseudoangiomatosis, which
consists of spontaneously regressing vascular papules com-
posed of telangiectatic vessels, but without a proliferative
component.97,98
Histopathologically, HFMD lesions show intraepidermal
vesicles with prominent reticular degeneration and a few
ballooned cells. No multinucleate cells or inclusion bodies
have been described in lesions of HFMD. Usually, there is
accompanying papillary dermal edema and a mild perivascular
inﬂammatory inﬁltrate mostly composed of lymphocytes.
Electron microscopic studies demonstrate viral particles.99 From
an immunohistochemical point of view, there is a commercially
available antibody that reacts with an epitope on the VP1 pep-
tide, which is highly conserved within the enterovirus group.100
This antibody reacts with a molecule of 34–37 kDa molecular
weight, and it was generated by using coxsackie B5 as immu-
nogen. It reacts with most enteroviruses of echovirus, coxsackie
and poliovirus group, but does not react with rotavirus, yellow
fever virus, measles, rhinovirus A1, adenovirus 18, or hepatitis
A virus.101 In our experience, this generic anti-enterovirus anti-
body stains mostly keratinocytes of the acrosyringium in
lesional skin (Fig. 5).
FIGURE 4. Histopathologic and immu-
nohistochemical findings in the exan-
thema of patient with measles. A,
Scanning power showing apparently
normal skin. B, Higher magnification
demonstrated isolated necrotic kera-
tinocytes in the epidermis and mild
superficial perivascular lymphocytic
infiltrate. C, The same case im-
munohistochemically studied with
the antibody for measles virus. D,
Immunoexpression is seen in the
nuclei of epidermal keratinocytes,
keratinocytes of the hair follicle, and
lymphocytes of the dermal infiltrate
(A and B, hematoxylin–eosin stain; C
and D, IHC for measles antibody;
original magnifications: A ·10,
B ·400, C ·10, and D ·200).
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RETROVIRUSES
Human T-Cell Lymphotropic Virus Type 1
Human T-cell lymphotropic virus type 1 (HTLV-1), also
named human T-cell leukemia virus type 1 and adult T-cell
lymphoma virus type 1, is endemic in the south of Japan and in
the Caribbean Islands and rare in other regions. Transmission
of HTLV-1 occurs primarily by sexual intercourse, blood
transfusions, needle sharing among intravenous drug abusers,
and breastfeeding. HTLV-1 induces T-cell proliferation, fol-
lowed by interleukin (IL)-2 receptor exposition, increased IL-2
secretion, and induction of interferon-g, IL-5, and IL-10.
HTLV-1 is associated with infective dermatitis and adult
T-cell leukemia/lymphoma (ATLL). Infective dermatitis is an
exudative and eczematous dermatosis that involves mostly the
scalp, axillae, groin, and small folds of the face.102 In some
cases, infective dermatitis may progress to more severe
HTLV-1–associated disease, such as ATLL. Four variants of
ATLL are recognized in the new World Health Organization
classiﬁcation of tumors of hematopoietic and lymphoid tis-
sues103: acute and chronic leukemic, lymphomatous, and smol-
dering types. Although cutaneous manifestations are usually
seen in the smoldering form of the disease, it has been suggested
that patients with purely cutaneous lesions may have a better
prognosis and should be classiﬁed separately from those with
smoldering ATLL.104 Cutaneous manifestations and histopatho-
logic features of ATLL are identical to those of mycosis fun-
goides, so demonstration of retroviral infection is mandatory for
diagnosis. Molecular analyses show a monoclonal rearrange-
ment of the TCR gene and the presence of the integrated
genome of HTLV-I.105 In the early phase of the ATLL, neo-
plastic cell properties dependent on the HTLV-1 proviral DNA
pX region p40Tax protein (Tax)101–109 appear under the effects
of external and internal mutagens110–112 following the accumu-
lation of mutations induced by repeated Tax expression113 in the
background of persistent proliferation of HTLV-1–infected T
cells, which is probably induced by HTLV-1 basic leucine zip-
per (HBZ) messenger RNA.114,115 Then, late-phase ATLL
cells with neoplastic properties independent of Tax appear
when mutation has progressed in the host cell DNA and
HTLV-1 proviral DNA, including pX p40Tax DNA
sequence.110 Histopathological diagnosis of ATLL is ex-
pected based on IHC detecting of Tax, HTLV-1 proviral
DNA pX p27Rex protein (Rex), or HBZ messenger RNA/
protein in neoplastic cells116 (Fig. 6).
FILOVIRUSES
The family Filoviridae is an unique negative-stranded
RNA virus family that forms ﬁlamentous virions. Not much is
known about ﬁloviruses because their highly pathogenic
nature makes them difﬁcult to study. Two members of the
family that are commonly known are Ebola virus and
Marburg virus.117 Both viruses, and some of their lesser
known relatives, cause severe disease in humans and nonhu-
man primates in the form of viral hemorrhagic fevers.
Ebola Virus
Ebola virus causes a severe and often fatal hemorrhagic
fever.117 Ebola hemorrhagic fever (EHF) is a rare disease, and
FIGURE 5. Histopathologic and immu-
nohistochemical findings in cutaneous
lesions of a patient with HFMD. A,
Scanning power showing severe epi-
dermal involvement. B, Higher magni-
fication demonstrated intraepidermal
vesicle with prominent reticular degen-
eration and a few ballooned cells. C,
The same case immunohistochemically
studied with the monoclonal anti-
body that reacts with the VP1 peptide
of the enterovirus group. D, Im-
munoexpression for VP1 peptide of
the enterovirus group is seen in epi-
dermal keratinocytes and acrosyr-
ingeal keratinocytes (A and B,
hematoxylin–eosin stain; C and D,
IHC for enterovirus antibody; original
magnifications: A ·10, B ·40, C ·10,
and D ·200).
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the number of sporadic cases occurring in tropical Africa is
unknown. The clinical diagnosis of EHF is often presumptive,
and laboratory conﬁrmation is essential. Traditionally, the
laboratory diagnosis of EHF has been accomplished through
virus isolation or serologic assays.118,119 Because of the bio-
safety hazards associated with the handling and testing of
EBO virus, these assays can be performed in only a few
specialized laboratories worldwide, requiring transportation
of the dangerous biological specimens from remote sites to
these laboratories.
In 1999, Zaki et al120 reported the development of
a novel, safe, sensitive, and speciﬁc diagnostic immunohisto-
chemical test for Ebola virus infections, which uses formalin-
ﬁxed postmortem skin specimens, and should be useful for
EHF surveillance and prevention. This antibody is not com-
mercially available. These authors evaluated skin biopsies of
14 patients during the EHF outbreak in the Democratic
Republic of Congo in 1995. They found abundant viral anti-
gens and particles within endothelial cells, mononuclear
phagocytic cells, and ﬁbroblasts in the skin of EHF patients
using IHC, thus suggesting an epidemiologic role for contact
transmission. Histopathologic changes in the skin tissue were
not pathognomonic and consisted mainly of various degrees
of endothelial cell swelling and necrosis.
CONCLUSIONS
IHC is an excellent diagnostic technique with the
distinct advantage of being able to exactly locate a given
protein within the tissue examined. The ﬁeld is continu-
ously expanding, with new applications steadily increasing.
Ultimately, the possibilities of IHC in the ﬁeld of
cutaneous viral infections are immense, and the future is
very promising.
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FEBRUARY 2015
Please mark your answers on the ANSWER SHEET.
Upon completion of this learning activity, participants should be better able to use immunohistochemistry (IHC) to
identify viral pathogens that are relevant to dermatopathology and apply these techniques in the diagnosis of cutaneous viral
infections and other related diseases.
1. Which of the following entities are PVB19-related dermatologic diseases?
a. Erythema infectiosum (ﬁfth disease)
b. Roseola infantum
c. Purpuric “gloves-and-socks” syndrome (PPGSS)
d. b and c
e. a and c
2. To which of the following diseases has Merkel cell polyomavirus been related?
a. Squamous cell carcinoma
b. Merkel cell carcinoma
c. Melanoma
d. a and b
e. b and c
3. Immunohistochemical studies have detected the measles virus in lesional skin within endothelial cells of:
a. Dermal capillaries
b. Epidermal multinucleate cells and lymphocytes
c. Keratinocytes of the upper layers of the epidermis
d. Hair follicles and sebaceous glands
e. All of the above
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4. Hand-foot-and-mouth disease (HFMD) is an exanthematous disease caused by:
a. Herpes viruses
b. Papillomaviruses
c. Poxviruses
d. Enteroviruses
e. Parvoviruses
5. Which of the following monoclonal antibodies has proved higher sensitivity in detecting MCPyV large T antigen when used
in skin biopsy specimens?
a. CM2B4
b. LNA-1
c. CM5E1
d. Ab3
e. LMP1
6. Trichodysplasia spinulosa has been recently associated with a new virus included in the family of:
a. Herpesviridae
b. Papillomaviridae
c. Polyomaviridae
d. Parvoviridae
e. Poxviridae
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What’s already known about this topic? Many dermatologic diseases have been linked to 
Parvovirus B19 infection due, among other evidence, to presence of viral Deoxyribonucleic 
acid (DNA) in tissue specimens. 
What does this study add? Polymerase chain reaction (PCR) detection of viral DNA in 22% 
of 1,825 tested cases confirms data of previous shorter series and casts doubts on a 
pathogenic role for Parvovirus B19 in these conditions. 
 
Summary 
Background: Human parvovirus B19 (B19V) has been associated with a number of 
dermatologic and systemic conditions, including myocarditis and autoimmune syndromes. 
Objectives: To determine the frequency of B19V deoxyribonucleic acid (DNA) detection 
in a large dermatopathology practice, and to characterize the histopathologic patterns 
involved. 
Methods: We selected for polymerase chain reaction (PCR) detection of B19V a total of 
1,815 skin biopsies pertaining to entities allegedly related to Parvovirus B19, as well as cases 
suspected clinically of representing paraviral exanthemas. Immunohistochemical detection of 
B19V viral protein 2 (VP2) was performed in 92 PCR-positive cases. 
Results: B19V DNA was found by PCR in 402 out of 1,825 biopsy specimens (22%). 
VP2 protein was identified by immunohistochemistry only in three instances of papular 
purpuric “gloves and socks” syndrome. 
Conclusions: Since the virus has the capacity to persist in different tissues (including the 
skin) for long periods, it could represent merely an innocent bystander, so no pathogenetic 
significance can be inferred from the PCR positivity for B19V in the vast majority of 
dermatologic conditions studied. 
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Introduction 
Human parvovirus B19 (B19V), the best known parvovirus able to infect humans,1,2 is 
responsible for a variety of diseases, including fifth disease (erythema infectiosum), cases of 
non-immune fetal hydrops, aplastic crises in patients with increased erythropoiesis, anemia in 
immunodeficient and immunocompromised patients, and acute or chronic arthropathy.3 Three 
genotypes of B19V are recognized, differing in over 10% of their genome:2 genotype 1 (by 
far worldwide predominant), genotype 2 (apparently restricted to subjects born before 1973), 
and genotype 3 (detected in West Africa and in only a few Western countries). The virus was 
first described in 1975 in the serum of nine healthy blood donors, a patient with acute 
hepatitis and another with a recent renal transplant, as false-positive results during routine 
screening for hepatitis B virus surface antigen.4 In 1983 it was found out that B19V is the 
cause of erythema infectiosum.5 In primary infection in adults, four clinical dermatologic 
patterns (exanthema, “gloves and socks”, periflexural and palpable purpura) have been 
recently delineated;6 these can rarely appear in combination.7 On the other hand, a role for 
B19V has been proposed in about 40 dermatologic conditions. These range from uncommon 
entities with a strong etiological association to B19V, like papular-purpuric “gloves and 
socks” syndrome (PPGSS)8 to classical dermatologic diseases with only an a priori remote 
relation with the virus. These include Henoch-Schönlein purpura, erythema nodosum, 
erythema multiforme, palmar desquamation/keratolysis exfoliativa, dermatomyositis-like 
rash, acute livedo reticularis, chronic urticaria, systemic sclerosis, chronic and acute pityriasis 
lichenoides, psoriasis, Behçet’s disease, granuloma annulare, necrotizing vasculitis, Wells 
syndrome, Melkerson-Rosenthal syndrome, hydroa vacciniforme, acute exanthematous 
pustulosis, Sweet’s syndrome and others.9-38This association has been mostly based on 
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serological proof of recent infection (i.e., IgM followed by IgG positive serology), or on the 
detection of viral DNA by PCR in serum or skin biopsies.10,17,20,23,25,38,39 Apart from erythema 
infectiosum, viral protein or RNA in skin biopsies has only rarely been demonstrated by 
immunohistochemistry and/or reverse transcriptase-polymerase chain reaction (RT-
PCR).17,40,41 
 
The mere detection by PCR of viral DNA in a tissue sample has been challenged as proof of 
a definitive causal role for B19V, since PCR investigation has yielded positive results in 
normal skin, chronic urticaria, and a number of disparate dermatological conditions.25,27,42-45 
For this storage mechanism for the virus, the term bioportfolio has been proposed.42 This 
suggests that B19V is in most settings but an innocent bystander, and questions its pathogenic 
role not only in dermatological diseases, but also in a number of medical conditions that 
along the years have been associated with it, like myocarditis.46 We have sought to explore 
the frequency at which B19V DNA can be found by PCR in formalin-fixed, paraffin-
embedded tissue of skin biopsies of a wide variety of cutaneous disorders in a large 
dermatopathology practice. With this aim, we undertook PCR study of B19V DNA in 1,815 
routine and consultation dermatopathology cases, with selection criteria based on data from 
the published dermatologic literature on the subject. The gamut of clinically suspected 
dermatologic conditions and the histopathologic patterns found in skin biopsies positive for 
B19V DNA are discussed. 
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Materials and methods 
Case selection 
A total of 1,815 cutaneous biopsy specimens from 1,749 patients were selected for PCR 
detection of B19V. Criteria for selection were either 1) derived from the accompanying 
clinical information on the request form (suggesting a clinical diagnosis of erythema 
infectiosum, reticulate or other form of exanthema of possible viral origin, or PPGSS; 2) a 
histopathologic pattern suggestive of virus-related exanthema, particularly when a superficial 
perivascular lymphocytic infiltrate accompanied by extravasated red blood cells or an 
interstitial granulomatous dermatitis pattern (as described in 2000 by Magro et al10), were 
present, or 3) clinico-histopathologic diagnosis of some of the nosological entities or 
dermatologic pictures that have been related to B19V infection in the medical literature.  
Clinical data and histopathology review 
All available medical records, laboratory data and glass slides (haematoxylin and eosin in 
all cases, and special stains and immunohistochemical study for VP2 structural protein when 
performed) were reviewed by two of the authors (CS and LR). The clinical diagnoses (as 
suggested by the physicians submitting the cases on requisition slips) and the histopathologic 
patterns found in the biopsies were grouped and tabulated.  
Immunohistochemistry 
Among the PCR-positive cases, 92 cases were selected for immunohistochemical study of 
VP2 protein. These corresponded to 3 instances of PPGSS and 89 cases arbitrarily selected 
because of a histopathologic picture comprising perivascular mononuclear inflammation, red 
blood cell extravasation and mild epidermal changes, similar to the findings in PPGSS. 
Polyclonal Rabbit Anti-Parvovirus B19 VP2 protein (DakoCytomation, Denmark) was used, 
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and visualization was achieved with Dako EnVision system. Positive and negative controls 
were simultaneously studied. 
Polymerase chain reaction 
Detection of Parvovirus B19 was performed from DNA isolated from formalin-fixed, 
paraffin-embedded tissue.27 Briefly, amplification of 50 ng DNA using specific primers for 
the B19V genome17 was performed in a PTC 200 thermocycler (MJ Research, Inc. 
Watertown, Massachusetts, USA) with 50 pmol of each primer, 10 mM Tris-HCl, 50 mM 
KCl, 1,5 mM MgCl2, 200 mM of each dNTP, 1,5 U Taq-Polmerase. The initial annealing 
temperature was 65ºC decreasing to 55ºC for the final 35 cycles. Sequencing of the 422 bp 
PCR product was carried out with the dye terminator sequencing kit (Amersham Pharmacia 
Biotech, Freiburg, Germany) following the instructions of the suppliers. In every PCR run 
two mixes without DNA and two mixes with Parvovirus B19 DNA from formalin fixed, 
paraffin embedded tissue were used as negative and positive controls, respectively (with 8 
samples at maximum). All PCRs, including the controls, were done in duplicate. All negative 
controls gave negative results. 
 
Results 
B19V DNA was detected in 402 out of 1,815 biopsy specimens (22%) from 394 patients. 
B19V VP2 structural protein was detected by immunohistochemical study only in the 3 
instances of PPGSS (as reported elsewhere40), with involvement of endothelial cells of small 
blood vessels of the papillary dermis (Fig. 1). This consisted of granular positive material 
within the cytoplasm of endothelial cells; no staining was observed in the nuclei of the 
endothelial cells.  
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247 patients were female, 145 were male, and in 2 patients sex was not specified in the 
accompanying report and could not be assigned. Age range was 4 to 82 years of age (mean, 
35.3; median 35; standard deviation 16.3). Site of biopsied lesions was the head in 10 cases 
(2.5%), trunk in 108 cases (26.8%), and extremities in 222 cases (55.1%); in 62 cases 
(15.4%) no information was given as to site of biopsy. 
Histopathologic prevailing patterns of inflammation and their frequencies are detailed in 
Table 1. Although in these biopsies there was a clear predominance of perivascular 
inflammation, including variants with lichenoid pattern, ballooning or spongiosis of the 
epidermis, other histopathologic inflammatory patterns were also represented. The proposed 
clinical diagnoses in the requisition slips were tabulated. Since in many cases more than one 
diagnosis was suggested, the total number of entries amounts to 586. A total of 111 
individual proposed clinical diagnoses were identified, covering a wide spectrum of 
dermatologic entities, which we have clustered in 11 groups (Table 2, supplementary 
material). Most frequent were the clinical diagnoses of vasculitis (40 instances), pityriasis 
lichenoides (38), pityriasis rosea (33), dermatitis/eczema (27), lichen planus/lichen nitidus 
(19), psoriasis (18), purpura (18), erythema chronicum migrans/borreliosis (17) and 
granuloma annulare (16). In 10 or more cases the proposed diagnoses were drug eruption, 
viral exanthema, lupus erythematosus, allergic vasculitis, lymphoma, parapsoriasis, 
sarcoidosis, urticaria, erythema multiforme and Sweet syndrome. No diagnosis was given or 
it was illegible in 29 instances. Final interpretation after histopathologic study was in many 
cases descriptive, with a comment regarding the most likely diagnosis in view of the 
submitted clinical information and proposed dermatologic diagnoses. 
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Discussion 
Our study firmly establishes that around 20% of skin biopsies harbour B19V DNA, 
expands the spectrum of clinical and histopathologic dermatologic conditions and patterns in 
which B19V DNA may be found, and casts doubts on the alleged etiopathogenic significance 
of a positive B19V PCR in cutaneous specimens. 
Eight years after its discovery in 1975, B19V was shown to be the cause of erythema 
infectiosum, a common childhood disease with a characteristic erythematous maculopapular 
rash (reticulated erythema) involving the trunk and the face of symptomatic patients, often 
resulting in a “slapped-cheek appearance”, which is most likely caused by immune complex 
deposition.5 In early studies, epidermal cells from a biopsy of the reticulated erythema in a 
child were shown to harbour viral proteins (by indirect immunofluorescence), and DNA (by 
in situ hybridization);9 likewise, viral particles (by electron microscopy) and viral protein (by 
immunohistochemistry) were identified in the cytoplasm of vascular endothelial cells in an 
adult patient.47 Other dermatologic conditions were later on associated with B19V infection 
in the light of serologic proof of recent infection and/or polymerase chain reaction (PCR) 
detection of B19V DNA (either in serum, tissue, or both). There is no doubt that acute B19V 
infection brings about either atypical exanthemas48 or a variety of dermatologic patterns, 
recently grouped by Mage et al into exanthema (reticulated and annular), gloves-and-socks, 
periflexural and palpable purpura.6 However, the assumption that detection of B19V DNA in 
a skin biopsy equals to pathogenicity seems no longer tenable, both from the available data in 
the literature in smaller series,25,42,44,45,49 and from the present, more comprehensive study. 
Earlier studies disclosed B19V DNA in 40% of 36 cutaneous biopsies of patients with 
urticaria, and in 64% of 22 healthy volunteers.25 In their 2006 paper proposing the concept of 
Bioportfolio, Norja et al studied, apart from the skin, samples from synovium, tonsil, liver 
and serum, and found 48% positivity in a series of 140 cutaneous biopsies from “B19-
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unrelated dermatological lesions(…) and from healthy hospital staff”.42 29 out of 38 skin 
biopsies for conditions unrelated to B19V were positive for viral DNA in the work of 
Corcioli et al.49 Our 22% figure is close to that in the study by Bonvicini et al,45 in which 
B19V DNA was detected by PCR and in situ hybridization techniques in 28% of pytiriasis 
lichenoides biopsies, 26% of melanocytic naevi, 17% of primary melanomas and 25% of 
normal skin specimens (total number of skin samples, 121). Higher values were found by 
nested and semiquantitative PCR by Sidoti et al: 40% of healthy skin controls, 41% of a 
variety of inflammatory dermatoses (psoriasis, atopic dermatitis, contact dermatitis, drug 
reactions, drug-versus host disease), and 34% of cutaneous T-cell lymphomas (total number 
of biopsies, 198). harboured B19V DNA.44 The skin appears therefore to be but one of the 
many organs in which B19V can be detected both in healthy individuals and in patients with 
diverse dermatologic ailments.  
Other than the skin, the list of healthy and diseased tissues allegedly harbouring B19V DNA 
or VP2 protein includes, in alphabetical order, bone marrow, brain, colon, heart, kidney, 
liver, lung, lymphoid tissue, small intestine, stomach, synovium, testis and thyroid.50,51This 
has led to claims of involvement of the virus in acute myocarditis and dilated 
cardiomyophaty,52 Kikuchi-Fujimoto disease,53 malignant lymphomas,54 non-occlusive 
gangrene of stomach and bowel,51 colon carcinoma,55 testicular neoplasia,56 and thyroid 
disorders.57 The initial enthusiasm in the cardiology literature has somewhat subsided, in 
view of the evidence for lifelong persistence of B19V DNA in the myocardium.58 The 
mechanism of viral persistence is unknown, but it is hypothesized (but by no means proven) 
that the virus might establish a latent-like type of infection, with harmless low DNA level 
resulting from inability to replicate in non-permissive cells;50 however, the possibility of 
reactivation can not be ruled out59 
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The tropism of B19V for endothelium, due to endothelial cells also expressing the viral 
receptor P antigen60 has been studied by several means. On the few reported 
immunohistochemical investigations of cutaneous biopsies for VP2, endothelial positivity has 
been so far restricted to the cytoplasm,17,40,47 although involvement of endothelial cell nuclei 
has been elegantly demonstrated in placental chorionic villi.61 The finding of B19V protein, 
DNA and messenger ribonucleic acid, supports a role for B19V in vascular lesions that can 
lead to full-blown pathologic syndromes, including myocardial infarction/myocarditis,62 
systemic sclerosis,63 vasculitis and autoimmune disorders.41,64 In the context of 
cardiomyopathy, a role for B19V infection of bone-marrow derived circulating angiogenic 
cells has been recently suggested; this would lead to dysfunctional vascular repair in the 
myocardium.65 Of note, it has recently been proposed66 that the predominant mechanism of 
infection of endothelium by B19V involves antibody-dependent enhancement, with 
interaction between the virus-antibody complexes and factor C1q and its receptor, CD93. 
This would be in keeping with the detection of VP2 in the endothelium in our PPGSS cases, 
but it remains to be seen whether it represents evidence of an abortive infection or a 
productive one leading to apoptosis or to an inflammatory immune response.2 
In summary, there is a wide array of dermatologic lesions, both from a clinical and a 
histopathologic standpoint, in which B19V DNA can be detected by PCR. In the absence of 
other proofs of recent infection, this finding is not particularly supportive of any 
etiopathogenic role for the virus in this varied group of cutaneous ailments. 
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Table 1 Patterns of inflammation/histologic findings in 402 biopsy specimens in which 
B19V DNA was detected by PCR 
 
 
Histologic Pattern Number of cases (%)
Perivascular only 72 (18%) 
Perivascular with lichenoid 
infiltrate 
68 (17%) 
Perivascular with cell 
ballooning 
11 (2.7%) 
Perivascular with spongiosis 79 (20%) 
Perivascular with psoriasiform 
epidermal hyperplasia 
10 (2.4%) 
Nodular with predominance of 
lymphocytes 
3 (0.7%) 
Nodular with predominance of 
histiocytes 
20 (5%) 
Diffuse with predominance of 
lymphocytes 
3 (0.7%) 
Diffuse with predominance of 
neutrophils 
11 (2.7%) 
Diffuse with predominance of 
histiocytes 
8 (2%) 
Small vessel vasculitis 23 (5.7%) 
Large vessel vasculitis 1 (0.2%) 
Vaso-occlusive vasculitis 1 (0.2%) 
Intraepidermal vesicular 2(0.5%) 
Melanocytic Naevus 2 (0.5%) 
Ulceration 1 (0.2%) 
Normal skin 1 (0.2%) 
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ABSTRACT 
 
Human Parvovirus B19 (B19V) causes a number of skin exanthemas and has been 
related to both cutaneous and systemic diseases. Tropism of the virus for the rapidly 
proliferating erythroid progenitor cells in the bone marrow and fetal liver explains the 
pathogenesis of anemia and fetal hydrops. The cutaneous lesions of erythema 
infectiosum and other B19V-related exanthemas have been attributed to deposition of 
immune complexes in the skin. We report on the immunohistochemical detection of 
B19V protein in the cytoplasm of dermal endothelial cells in a case of periflexural 
exanthema in a 28-year-old woman. An antibody-dependent enhancement mechanism 
of entry has been suggested for B19V in myocardial endothelial cells, and could also be 
involved in B19V-related exanthemas. 
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INTRODUCTION 
Primary infection by Human Parvovirus B19 (B19V), the etiological agent of erythema 
infectiosum in infancy and childhood, can result in cutaneous lesions in adults, with 
patterns designated as exanthema, “gloves and socks”, periflexural and palpable purpura 
[1] that can either appear isolated or overlap. Moreover, around 5% of atypical 
exanthemas (i.e. those whose morphology and etiology depart from the six classical 
ones) [2] have been found to be related to B19V infection, both in children and in 
adults. These skin manifestations are thought to be due to specific immunological 
reaction to the virus. In the rarely biopsied cases of primary B19V infection, a dermal 
mononuclear perivascular lymphocytic infiltrate with erythrocyte extravasation, as well 
as leukocytoclastic vasculitis, have been reported. Immunohistochemistry has 
surprisingly been used only anecdotally, but it can reveal viral proteins in epidermal 
keratinocytes or within endothelial cells of the superficial dermis, a finding of uncertain 
significance. [3,4] We report for the first time on the immunohistochemical detection of 
B19V VP2 protein within dermal endothelial cells in periflexular and purpuric 
involvement in primary B19V infection in an adult patient, review previous reports in 
the literature and discuss the possible relationship of this finding with the recently 
described antibody-mediated enhancement (ADE) as uptake mechanism of B19V. [5] 
 
 
 
 
 
  
MATERIALS AND METHODS 
 
The skin biopsy was fixed in formalin and embedded in paraffin. 5-micron sections 
were stained with hematoxylin&eosin. Immunohistochemical study of B19V viral 
protein 2 (VP2) structural protein (Polyclonal Rabbit Anti-PVB19, DakoCytomation, 
Denmark) was performed following the manufacturer´s instructions and was visualized 
with DAKO EnVision system. Liver tissue from a B19V-associated fetal hydrops was 
used as positive control. Polymerase chain reaction (PCR) techniques for molecular 
detection of B19V were performed according to Aractingi et al. [3] The serological 
detection of antibodies against B19V was done by enzyme-linked immunosorbent 
assay. 
 
RESULTS 
 
Clinical History 
A 28-year-old caucasian woman was seen at the Emergency Department of Fundación 
Jiménez Díaz with a 24-hour history of fever, pruritus and a rash. She described the 
latter as macules and papules that had first appeared on her vulva, inguinal folds and 
thighs, spreading later on to her axillae, arms and legs. Her previous medical history 
included type II diabetes, obesity and a non-secreting pituitary microadenoma 
diagnosed several years earlier in Cuba (her home country), for which she received 
Linagliptin and Metformin. On admission, her temperature was 37.6ºC. She had mild 
tachycardia and normal blood pressure. On examination, an extensive exanthema of 
erythematous papules with petechial lesions was observed involving particularly axillae, 
anogenital region, inner thighs, buttocks and antecubital fossae (Figure 1). She had no 
lesions in oral mucosa, palms or soles. Laboratory data showed leukocytosis (15,820 
cells per microliter), with neutrophilia, mild hyperglycemia (serum glucose 127 mg/dl), 
and a mixed hyperbilirubinemia. Serum tryptase levels were normal. Urinalysis 
disclosed pyuria, hematuria and bacteriuria. Abdominal ultrasonography and CT-scan 
revealed cholelithiasis with no signs of cholecystitis, and left renal lithiasis without 
dilatation of the excretory system. With the clinical suspicion of urinary versus biliary 
tract infection the patient was admitted, receiving antibiotic coverage and 
antihistamines. Dermatological evaluation the following day suggested baboon/like 
syndrome caused by primary Parvovirus B19 infection. Clinical evolution was 
favorable, with disappearance of fever and gradual fading of her cutaneous lesions over 
the course of 7 days. During her hospital stay she developed pancytopenia, with nadir 
values of white cell count, hematocrit and platelets of 1,360 cells/µl, 29.6 %, and 
102,000 cells /µl respectively. All these parameters spontaneously had returned to 
normal four weeks later. Serologic results for hepatitis A, B, and C, syphilis, HIV, 
Epstein-Barr virus, cytomegalovirus, rheumatoid factor, and antinuclear and 
antineutrophil cytoplasmic antibodies were negative. A serologic test for Parvovirus 
B19-specific IgM antibodies to viral capsid antigen was positive. 
 
Pathologic Features 
A skin biopsy performed on the 3rd day of admission showed unremarkable epidermis 
and a moderate, mostly perivascular mononuclear inflammatory infiltrate with some 
eosinophils and rare extravasated erythrocytes (Figure 2). No evidence of vasculitis was 
seen. An immunohistochemical study for B19V VP2 protein revealed positive granular 
material within the cytoplasm of superficial dermal blood vessels (Figure 3). 
 
DISCUSSION 
 
Primary infection by B19V (family Parvoviridae, genus Erytrhoparvovirus, species 
Primate erythroparvovirus 1) is involved in two dermatological conditions with distinct 
cutaneous eruptions, namely erythema infectiosum in childhood and papular and 
purpuric “gloves and socks syndrome” (PPGSS) in adults. It can also cause other 
exanthemas in adults and children, designated palpable purpura, periflexural and 
atypical exanthemas. [1] [2]Serological conversion (i.e. IgM followed by IgG positive 
serology) and detection of viral deoxyribonucleic acid (DNA) in serum by PCR have 
linked these dermatologic manifestations to PVB19. The presence of B19V 
deoxyribonucleic acid (DNA) in biopsy specimens needs to be matched to serum 
samples, in order to confirm an acute infection, since the virus can persist for a long 
time in a number of tissues, including the skin. [6,7] Thus, the wide array of cutaneous 
ailments that along the years have been assumed to be related to PVB19 needs to be 
critically reviewed, accepting only those instances in which seroconversion and/or 
serum B19V can be proven (Table 1) 	  
[3,8-37] 
 
The specific tropism of PVB19 for bone marrow erythroid progenitor cells (due to their 
expression not only of the globoside receptor/P antigen but also of co-receptors 
Alpha5Beta1 integrin and Ku80), and the consequent cessation of erythropoiesis explain 
some of the pathological conditions with which PVB19 is associated: anemia in 
immunocompromised patients, transient aplastic crises and hydrops fetalis.[38] Other 
ailments, such as arthropathy and the above mentioned cutaneous eruptions, have been 
attributed to viral activation of synoviocytes or to deposition of immune complexes, 
respectively. [39,40]  
Few reports have addressed the cutaneous histopathologic findings of exanthemas 
caused by PVB19. The described lesions consist for the most part of extravasation of 
erythrocytes and a perivascular lymphohistiocytic infiltrate [3,4,41,42], but other 
patterns have been reported, among them vesicular, bullous or pustular lesions [43] 
[32,44], necrosis of keratinocytes [25] , interface dermatitis [27] , interstitial 
eosinophilic infiltrates [30] and cutaneous vasculitis [18,21,29,45] (Table) 
Other than by means of PCR detection of B19V DNA, a specific search of B19V virion 
components in skin specimens has been performed occasionally. As early as 1994, 
Schwarz et al [46] described the presence of B19V viral particles by electron 
microscopy (EM) and indirect immunofluorescence within cells of the epidermis in a 
skin biopsy of the exanthema of erythema infectiosum in a child. One year later, 
Takahasi et al reported the involvement of vascular endothelial cells in an adult patient 
with primary B19V infection, demonstrating within their cytoplasm viral particles by 
EM and viral protein by immunohistochemistry. No immune complexes were identified 
by immunofluorescence, although C3 was deposited in the perivascular regions of the 
dermis. [47] A few years later, viral proteins were detected by immunohistochemistry in 
in three cases of papular-purpuric “gloves and socks” syndrome (PPGSS). The staining 
was seen not only in dermal endothelial cells, but also in keratinocytes and sweat gland 
epithelial cells. [3] In situ reverse transcriptase PCR (RT-PCR) was used by Magro et al 
[48] to demonstrate viral RNA in endothelial cells (and adjacent mononuclear cells) in 
skin biopsy specimens of several patients with positive IgG/IgM B19V serology and 
clinical manifestations of connective tissue disease (including petechial and purpuric 
eruptions and confluent rashes). The same method was employed to demonstrate the 
virus in cases of endothelialitis allegedly secondary to B19V infection. [49] [50] 
Finally, positive immunohistochemical staining of the endothelium was reported in 
2011 in three instances of PPGSS. [4]This study was negative in an additional case of 
mixed PPGSS and “bathing trunk” eruption.[37] In all cases in which the endothelium 
has been shown to contain B19V VP2 by immunohistochemistry, this was restricted to 
granular material within the cytoplasm of endothelial cells, even though nuclear 
localization of this protein should be expected and has been elegantly demonstrated in 
infected placental tissue with the same technique [51] 
In the natural history of PB19V infection, an initial viremic phase (clinically 
undetected) allows the virus to gain access to permissive bone marrow erythroid 
progenitor cells, where they actively replicate and cause apoptosis, with release of 
progeny virus in the blood.[52] The normally nonpermissive endothelium has been 
recently shown to allow the entrance of PVB19 by means of ADE (in which B19V-
antibody complexes use complement factor C1a and CD93 surface protein to facilitate 
endocytosis)[5]. Thus, the immune response to the virus in form of IgM antibodies 
contributes to its spread to other tissues, including the skin, synovial joints or 
endothelial cells of the myocardium. This infection, however, seems to be 
nonproductive, so that only under specific conditions (hypoxia, cytokine stimulation) 
would endothelial cells support the syntyhesis of viral proteins. [5]The detected VP2 in 
our case could represent unpackaged B19V particles, acquired by the ADE mechanism. 
It remains to be seen whether damage to the endothelium could follow, as has been 
speculated in the pathogenesis of B19V-related vasculitis and autoimmune diseases. 
[48,50,53] 
 In summary, we present the first case of B19V-related flexural-type exanthema with 
immunohistochemical demonstration of viral proteins within the cytoplasm of 
superficial dermal vessels endothelium, and propose that ADE-mediated uptake is 
responsible for this finding, as has been hypothesized for the endothelium of myocardial 
vessels. 
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Figure legends 
Figure 1. Papular and purpuric exanthema involving inguinal regions (a), antecubital 
fossa (b) and axillas (c,d) in a 28-year-old woman with fever and positive IgM for 
B19V. 
 
Figure 2. Histopathologic appearance of a skin biopsy, showing mild perivascular, 
mostly lymphohistiocytic inflammation. No evidence of vasculitis was found. 
 
Figure 3. Immunohistochemistry for B19V VP2. Note granular material within the 
cytoplasm of the endothelial cells of the upper dermis. 
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Table 1. Dermatologic clinical entities associated with B19V in the literature, pathologic findings 
 in biopsies and means of B19V detection. 
 
DISEASE/CLINICAL 
PATTERN 
PATHOLOGIC 
FINDINGS IN SKIN 
B19V 
Serum 
Antibodies 
Serum 
B19V 
Tissue 
B19V 
PCR 
IHC 
detection 
of B19V 
Erythema 
Infectiosum9,46,10 
No biopsy9 
No details given46 
Interstitial/perivascul
ar dermatitis10 
 
IgM ND ND ND 
Henoch-Schönlein11 No biopsy IgM ND ND ND 
Papular Petechial 
Vesiculopustular 
Eruption43 
Vesiculopustules, 
Eosinophils 
IgM, IgG ND ND ND 
Pruritic Macular 
Erythematous 
Rash12 
No biopsy IgM, IgG ND ND ND 
Revised Table
Pruritus, measles 
like rash12 
No biopsy IgM, IgG ND ND ND 
Pruritic rash12 No biopsy IgM, IgG ND ND ND 
Erythema 
nodosum13 
No biopsy IgM ND ND ND 
Erythema 
Multiforme14 
E. Multiforme IgM, IgG - ND ND 
Keratolysis 
Exfoliativa15 
No biopsy IgM, IgG ND ND ND 
Papular purpuric 
“gloves and socks” 
syndrome3,4 
Slight acanthosis, 
PVD, purpura 
ND 
IgM, IgG 
ND 
+ 
ND 
+ 
ND 
+ 
Morbilliform rash16 No biopsy IgM ND ND ND 
Gianotti-Crosti16 No biopsy IgM ND ND ND 
Purpura, Koplik 
spots17 
No biopsy IgM, IgG ND ND ND 
Palpable Purpura, 
Wegener 
Granulomatosis18 
Leukocytoclastic 
Vasculitis 
IgM, IgG + + - 
Livedo Reticularis 
and Myasthenia19 
Vascular 
Telangiectasias 
IgM - ND ND 
Polyarteritis 
Nodosa18 
Leukocytoclastic 
Vasculitis 
IgM, IgG + + ND 
Unilateral 
laterothoracic 
exanthem20 
PVD + Hemorraghe IgM, IgG - ND ND 
Papular Dermatitis 
Sweet-like 
Granuloma 
annulare–like 
Dermatomyositis–
like 
Lupus-like 
Palpable Purpura10 
Incipient GA: 
interstitial infiltration 
Interface Dermatitis 
Vasculitis, 
lymphocytic or 
granulomatous 
Dermal mucinosis 
Leucocytoclastic 
Vasculitis 
IgM, IgG ND + ND 
Connective Tissue 
Disease (DM, LE, 
Vasculitis, PAN)21 
Vacuolar Interface 
Dermatitis, incipient 
GA, mucinosis, PVD, 
Leucocytoclastic 
Vasculitis 
IgM, IgG - + ND 
Digital Ischemia22 No biopsy IgM, IgG ND ND ND 
Chronic urticaria 
Normal skin23 
Not described IgG - + ND 
Pseudo-cellulitic 
plaques24 
No biopsy IgM ND ND ND 
Pityriasis 
lichenoides25 
Wedge-shaped 
infiltrate, 
extravasated 
erythocytes, variable 
necrosis of 
keratinocytes 
ND ND + ND 
Baboon Syndrome-
like26 
PVD Hemorrhage 
Interface Dermatitis 
IgM + ND ND 
Asymmetric 
Periflexural 
Exanthem27 
Interface Dermatitis, 
Syringotropic 
lymphocytic infiltrate 
IgM, IgG ND ND ND 
Psoriasis28 
Not applicable IgG, IgM + ND ND 
Behçet’s Disease29 Leukocytoclastic 
vasculitis 
IgG ND + ND 
Wells’ syndrome30 Eosinophilic 
interstitial infiltrate 
with flame figures 
IgM, IgG + 
(ND) 
+(ND) ND 
Melkersson-
Rosenthal 
syndrome31 
Multiple granulomas 
in lip and paranasal 
sinus 
IgG + ND ND 
Hydroa 
vacciniforme32 
Intraepidermal bullae, 
lymphocytic dermal 
infiltrate 
ND ND + ND 
Sweet’s syndrome33 Dermal neutrophils, 
also lymphocytes and 
plasma cells 
IgM, IgGH ND ND ND 
Febrile 
ulceronecrotic 
Mucha-Habermann 
disease34 
Psoriasiform 
dermatitis, exocitosis 
of lymphoid cells, 
dermal edema and 
erythrocyte 
extravasation 
IgM, IgG + - ND 
Acute Exanthematic 
Pustulosis35 
Subcorneal pustules, 
dermal perivascular 
and interstitial 
inflammation 
IgM, IgG ND ND ND 
Flagellate 
Erythema36 
No biopsy IgM ND ND ND 
Papular purpuric 
“gloves and socks” 
syndrome and 
bathing-trunk 
eruption37 
 
Lymphocytic 
exocytosis, edema in 
dermis, extravasated 
red blood cells, 
perivascular 
lymphohistiocytic 
infiltrate 
IgM, IgG ND ND - 
Present Case 
Periflexural 
exanthema 
Perivascular 
mononuclear 
inflammatory 
infiltrate, eosinophils, 
extravasated 
erythrocytes 
IgM ND ND + 
 
 
PCR, Polymerase Chain Reaction; IHC, immunohistochemical; PVD, Perivascular Dermatitis; +, Positive; -, Negative; ND, Not Done 
 
